NRX Pharmaceuticals flags going-concern doubt
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
NRX Pharmaceuticals, Inc. reported third-quarter patient service revenue of $1.159 million, compared with $242,000 a year earlier, while net loss narrowed to $2.175 million from $5.890 million. For the nine months ended September 30, 2026, revenue was $3.328 million and net loss was $20.125 million; operating cash use was $19.882 million, versus $10.401 million a year earlier. Cash was $19.822 million at September 30, alongside a $7.0 million working-capital deficit. The company received approximately $11.8 million net from its at-the-market offering and approximately $20.7 million net from a June underwritten public offering of 6,378,942 shares at $3.50 each.
Management expects operating losses through at least the remainder of 2026 and concluded substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance. After quarter-end, the FDA approved a preservative-free ketamine product on October 29, 2026, and the product entered the commercial launch phase. NRx Defense Systems, Inc., a subsidiary, was awarded an $11.25 million DARPA contract in October to lead the SPARC-TMS clinical trial.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter patient service revenue reached $1.159 million, versus $242,000.
- Moderate pointThird-quarter net loss narrowed to $2.175 million from $5.890 million.
Negative
- Major pointGoing-concern substantial doubt extends at least 12 months from issuance.
- Moderate pointOperating cash use increased to $19.882 million from $10.401 million.
- Minor pointWorking-capital deficit was $7.0 million at September 30, 2026.
Filing Explained
The November 16 count is 44,327,982 outstanding shares; the filing separately lists 10,091,909 equivalents excluded from diluted loss per share.
As of
Separately, the filing lists 10,091,909 common-stock equivalents at
Key Figures
Key Terms
going concern financial
working capital deficit financial
at-the-market offering financial
Abbreviated New Drug Approval regulatory
SPARC-TMS clinical trial medical
transcranial magnetic stimulation medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were NRXP’s third-quarter revenue and net loss?
What FDA approval did NRXP receive after the third quarter?
What DARPA contract did NRXP’s subsidiary receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
For the Quarterly Period Ended:
For the transition period from to
Commission File Number:
NRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
| | | The |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| | Smaller reporting company |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of November 16, 2026, the registrant had
TABLE OF CONTENTS
| Page |
||
| PART I – FINANCIAL INFORMATION |
3 |
|
| ITEM 1. |
Financial Statements |
3 |
| Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 |
3 |
|
| Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 |
4 |
|
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 and 2025 |
5 |
|
| Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 |
7 |
|
| Notes to Unaudited Condensed Consolidated Financial Statements |
8 |
|
| ITEM 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
42 |
| ITEM 3. |
Quantitative and Qualitative Disclosures about Market Risk |
62 |
| ITEM 4. |
Controls and Procedures |
62 |
| PART II – OTHER INFORMATION |
63 |
|
| ITEM 1. |
Legal Proceedings |
63 |
| ITEM 1A. |
Risk Factors |
63 |
| ITEM 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
63 |
| ITEM 3. |
Defaults Upon Senior Securities |
63 |
| ITEM 4. |
Mine Safety Disclosures |
63 |
| ITEM 5. |
Other Information |
63 |
| ITEM 6. |
Exhibits |
64 |
| SIGNATURES |
65 |
|
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
NRX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Prepaid expense and other current assets | ||||||||
| Total current assets | ||||||||
| Investments | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets, net | ||||||||
| Right-of-use asset - related party, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued and other current liabilities | ||||||||
| Accrued clinical site costs | ||||||||
| Insurance loan payable | ||||||||
| Warrant liabilities | ||||||||
| Lease liability, short term | ||||||||
| Lease liability, short term - related party | ||||||||
| Total current liabilities | ||||||||
| Lease liability, noncurrent | ||||||||
| Lease liability, noncurrent - related party | ||||||||
| Total liabilities | ||||||||
| Commitments and Contingencies (Note 10) | ||||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized. | $ | $ | ||||||
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | ||||||||
| common stock, $0.001 par value, 500,000,000 shares authorized; 43,207,744 and 31,734,333 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders' deficit | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
NRX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net patient service revenue | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of patient services | ||||||||||||||||
| Research and development | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Settlement expense (income) | ( | ) | ( | ) | ||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expenses (income): | ||||||||||||||||
| Interest income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense | ||||||||||||||||
| Change in fair value of convertible notes payable | ||||||||||||||||
| Change in fair value of warrant liabilities | ( | ) | ||||||||||||||
| Loss on issuance of Registered Direct Offering | ||||||||||||||||
| Loss on Consideration Shares and Warrants | ||||||||||||||||
| Loss on convertible note conversions | ||||||||||||||||
| Gain on exercise of warrants | ( | ) | ( | ) | ||||||||||||
| Income from equity method investment | ( | ) | ( | ) | ||||||||||||
| Total other (income) expense, net | ( | ) | ||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common stock outstanding: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
NRX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
(in thousands, except share data)
(Unaudited)
| Series A Preferred | Additional | Total | ||||||||||||||||||||||||||||||||||
| Preferred Stock | Stock | Common Stock | Paid-in- | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Balance – December 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| At-the-market “ATM” offering, net of offering costs of $81 | — | — | ||||||||||||||||||||||||||||||||||
| Amortization of prepaid offering costs | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance – March 31, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| At-the-market “ATM” offering, net of offering costs of $188 | ||||||||||||||||||||||||||||||||||||
| Amortization of prepaid offering costs | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Common stock issued as a result of cashless exercise of warrants | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Common stock issued in exchange for services | ||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock awards | ||||||||||||||||||||||||||||||||||||
| Shares issued with underwritten public offering, net | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Stock-based compensation | — | — | 50,000 | |||||||||||||||||||||||||||||||||
| Common Stock issued in exchange for services | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Series A Preferred | Additional | Total | ||||||||||||||||||||||||||||||||||
| Preferred Stock | Stock | Common Stock | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Shares issued as repayment of principal and interest for convertible note | — | — | ||||||||||||||||||||||||||||||||||
| Shares issued with registered direct offering, net of offering cost | ||||||||||||||||||||||||||||||||||||
| Fair Value of warrants issued with registered direct offering | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Amortization of prepaid offering costs | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Shares issued as a result of repricing under VWAP | — | — | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Shares issued in exchange for services | ||||||||||||||||||||||||||||||||||||
| Shares issued as conversion of principal and interest for convertible note | ||||||||||||||||||||||||||||||||||||
| Amortization of deferred offering costs | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| At-the-market “ATM” offering, net of offering costs of $26 | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Common Stock issued as a result of exercise of warrants | ||||||||||||||||||||||||||||||||||||
| ATM offering, net of offering costs of $110 | ||||||||||||||||||||||||||||||||||||
| common stock issued in exchange for services | ||||||||||||||||||||||||||||||||||||
| Shares issued as repayment of principal and interest for convertible note | ||||||||||||||||||||||||||||||||||||
| Shares issued with registered direct offering, net of offering cost of $321 | ||||||||||||||||||||||||||||||||||||
| Amortization of prepaid offering costs | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
NRX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | ||||||||
| Amortization of operating right of use assets | ||||||||
| Stock-based compensation | ||||||||
| Common stock issued in exchange for services | ||||||||
| Provision for credit losses | ||||||||
| Change in fair value of warrant liabilities | ||||||||
| Change in fair value of convertible promissory notes | ||||||||
| Loss on convertible note conversions | ||||||||
| Gain on exercise of warrant liabilities | ( | ) | ||||||
| Loss on issuance of registered direct common stock | ||||||||
| Loss on Consideration Shares and Warrants | ||||||||
| Income from equity method investments | ( | ) | ||||||
| Expense for debt issuance costs due to fair value election on Anson Notes | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expense and other assets | ( | ) | ||||||
| Account receivable | ( | ) | ||||||
| Accounts payable | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Accrued expense and other liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | ( | ) | ||||||
| Business acquisition, net of cash acquired | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Repayment of insurance note | ( | ) | ( | ) | ||||
| Expense for debt issuance costs due to fair value election on Anson Notes | ( | ) | ||||||
| ATM offering, net of offering costs | ||||||||
| Proceeds from issuance of insurance loan | ||||||||
| Proceeds from issuance of common stock in underwritten public offering, net of issuance costs | ||||||||
| Proceeds from issuance of common stock and warrants issued in registered direct offering, net of issuance costs | ||||||||
| Proceeds from Anson convertible notes, net of OID | ||||||||
| Net cash provided by financing activities | ||||||||
| Net increase in cash and cash equivalents | ||||||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for taxes | $ | $ | ||||||
| Non-cash investing and financing activities: | ||||||||
| Issuance of common stock as principal and interest repayment for convertible notes | $ | $ | ||||||
| Goodwill adjustment | $ | $ | ||||||
| New right of use asset and lease liability | $ | $ | ||||||
| Amortization of deferred offering costs to additional paid-in capital | $ | $ | ||||||
| Exercise of the warrants for subscription receivable | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
NRX PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2026
(Unaudited)
Note 1. Business and organization
The Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a commercial-stage bio-pharmaceutical company that controls an ecosystem of Companies focused on the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (“PTSD”), ALS, Multiple Sclerosis, and schizophrenia.
NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (“HOPE”), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (“TMS”), digital therapeutics, and hyperbaric therapy. HOPE Therapeutics was founded by the Company in February 2024 with the intent of developing a medical care delivery organization focused on providing cutting-edge, comprehensive interventional psychiatric treatment with the most effective treatments available, including NMDA-targeted and other neuroplastic drugs, such as ketamine, Spravato and NRX-101, neuromodulatory devices, such as TMS, hyperbaric therapy, digital therapeutics, and medication management. During 2025, the Company developed the operating model for HOPE and made initial clinic acquisitions with funding from the B-Group. HOPE generated its first clinical revenue in Q4 2025 and as of September 30, 2026, operates in six locations in Florida, including Dura Medical, Cohen Associates, and three clinics founded by HOPE. The enterprise offers precision-based interventional psychiatry services, including ketamine infusion therapy, TMS, Spravato®, stellate ganglion blocks, and psychotherapy (See Note 16). HOPE is supported by HTX Management Company, LLC (“HTX”), a majority owned subsidiary of HOPE organized as a Delaware limited liability company, for the purpose of supporting future back-end operations associated with the growing network of HOPE clinics.
In its first year of operation, HOPE’s leadership recognized the widespread challenges affecting the TMS clinic industry and chose to partner in the development of innovative technologies with thought leaders at Harvard McLean hospital and the Yale Department of Psychiatry. This led to HOPE’s partnerships with Neurocare, AG, a German manufacturer of TMS equipment and Zeta Surgical, Inc., manufacturer of the first neuronavigated, robotic precision TMS system. This partnership led to NRx Defense Systems, Inc. ("NRXD") selection by DARPA to lead the SPARC-TMS trial. When combined with NRx’s NRX-101 oral medication, the Company aims to deliver precision and efficacy in treating depression and PTSD that surpasses currently available solutions. In the preamble to the DARPA contract, the Department of War states that success in the SPARC-TMS project has potential to set the standard of care for treating depression in the military.
During 2026, NRx founded NRXD as a qualified military contractor in response to an invitation from the Defense Advanced Research Projects Agency (DARPA) to submit a bid under their Broad Area Announcement. NRXD focuses on military and first-responder uses of NRx/HOPE technology in partnership with DARPA, the Uniformed Services Health Sciences University (USU), the Walter Reed National Military Medical Center/Henry Jackson Foundation, and first responder organizations. In October 2026, NRXD was awarded the $
During 2026, NRx also founded GeNeuro, Inc., a development-stage biotechnology company based on novel discoveries related to the role of Human Endogenous RetroViruses (HERVs) in causing neurodegenerative disease. HERVS are fossilized viruses that entered the human gene pool over the course of evolution and are considered part of the “dark genome.” Recent evidence demonstrates that when elements of HERVs aberrantly enter the “reading frame” and begin replicating in adult life, they may cause devastating neurodegenerative diseases. GeNeuro is developing GNK-301 for the treatment of ALS through its partnership with the U.S. National Institutes of Health (“NIH”) through a Cooperative Research and Development Agreement (CRADA) and shared patents and has been selected in the first round of the 2026 Congressionally Directed Medical Research Program (“CDMRP”). GeNeuro, Inc. is additionally partnered through shared patents related to treatment of Schizophrenia with the Fondation FondaMental of France. GeNeuro owns patented monoclonal antibodies developed with more than EU 180 million of European investment funding to treat Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), psychosis, and Type I diabetes (“T1D”) that may be caused by Human Endogenous Retroviruses (“HERVs”).
Since the end of the third quarter, the mission of the NeuroRx Pharmaceuticals division was expanded to encompass the manufacture and immediate commercial distribution of a broader array of sterile injectable products to meet urgent United States market demand. This expansion began with the grant of our first Abbreviated New Drug Approval by the US Food and Drug Administration on October 29, 2026 for a preservative-free ketamine product, which has now entered the commercial launch phase. The Company has recruited and trained a seventeen-person sales force and initiated marketing of the ketamine product with anticipated net margins that are consistent with innovative drugs. Efficiencies are driven by the innovative blow-fill-seal (BFS) packaging solution that is far less costly than traditional glass bottle packaging currently used in sterile injectable drugs. NeuroRx continues to develop innovative forms of ketamine to treat depression and PTSD (NRX-100/200) and an oral neuroplastic drug (NRX-101) that has demonstrated phase 2 proof of concept for suicidal bipolar depression and, more recently, for the augmentation of Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression.
Note 2. Significant accounting policies
Basis of Presentation and Principles of Consolidation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the condensed consolidated balance sheet, statements of operations, and cash flows for the interim periods presented. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. The condensed consolidated financial statements include the accounts of NRx Pharmaceuticals, Inc. and its wholly and majority owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity and Going Concern
The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has incurred recurring operating losses and negative cash flows from operations. For the nine months ended September 30, 2026, the Company reported a net loss of approximately $
The Company generated initial patient service revenue of approximately $
The Company has secured operating capital and contractual receivables that together with rising clinical revenues, anticipated pharmaceutical sales, and potential ATM proceeds provide anticipated resources sufficient to fund operations for the foreseeable future. The Company additionally expects to continue to accrue revenue from clinical operations and utilize its existing at-the-market offering to provide cash resources to further support operations. The Company may pursue additional equity or debt financing or refinancing opportunities to fund ongoing clinical activities and for general corporate purposes. Such arrangements may take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures, or other agreements. The sale of equity could result in additional dilution to the Company’s existing stockholders. The Company will continue to carefully monitor the impact of its continuing operations on the Company’s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. They do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded asset amounts and classifications of liabilities that might be necessary should the company be unable to continue as a going concern.
In addition, the Company's independent registered public accounting firm, in its report on the Company's consolidated financial statements for the year ended December 31, 2025, included an explanatory paragraph about the substantial doubt about the Company's ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty.
Use of Estimates
The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to the allowance for credit losses on accounts receivable, fair value of the convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, fair value of the shares of common stock shares granted for services, fair value of the purchase price and the assets acquired and liabilities assumed in business combinations, the fair value of intangible assets and goodwill, the fair value of lease liabilities and related right of use assets, and the utilization of deferred tax assets. Actual results may differ from these estimates.
Reclassifications
Certain prior year amounts have been reclassified to conform to the 2026 presentation.
Certain Risks and Uncertainties
The Company’s activities are subject to significant risks and uncertainties, including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.
Fair Value of Financial Instruments
FASB ASC Topic 820, Fair Value Measurements (“ASC 820”), provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.
The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:
Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation (Refer to Note 13).
Business Acquisitions
The Company recognizes and measures identifiable tangible and intangible assets acquired and liabilities assumed as of the acquisition date at fair value. Fair value measurements require extensive use of estimates and assumptions, including estimates of future cash flows to be generated by the acquired assets. The operating results of the acquired business are included in our consolidated financial statements beginning on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Acquisition-related costs are expensed as incurred.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return.
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. As of September 30, 2026, the Company’s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $
Accounts Receivable, net
Accounts receivable are recorded at the estimated transaction price (net of contractual adjustments, discounts, and implicit price concessions). The Company applies the Current Expected Credit Loss (“CECL”) model to estimate lifetime expected credit losses on trade receivables and contract assets, pooling receivables by payer type and aging and incorporating historical loss experience, current conditions, and reasonable and supportable forecasts with reversion to historical loss information beyond the forecast horizon. Receivables are written off when collection is deemed remote; recoveries are recognized when received. The Company does not have any off-balance sheet credit exposure related to its customers.
Intangible Assets
The Company’s intangible assets consist of customer relationships, trade name, and non-compete agreements. Customer relationships represent the value of established patient relationships and referral sources that are expected to generate recurring revenue streams. Trade name represents the value associated with the brand name in place at the date of the acquisition. The customer relationships and trade name are being amortized over a 3-year term and 10-year term, respectively, based on the estimated economic useful life of the customer relationships and trademark. The amortization of intangible assets is computed using the straight-line method.
The Company evaluates its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Such indicators may include adverse changes in market conditions, legal or regulatory developments, or underperformance relative to expectations. If indicators are present, the Company performs a recoverability test by comparing the asset’s carrying amount to the undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is recognized for the excess of the carrying amount over the asset’s fair value.
Goodwill
Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include, but not limited to, significant adverse changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors.
The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value.
Property and Equipment, net
Property and equipment, net is stated at cost less accumulated depreciation. These assets are depreciated over their estimated useful lives of five to seven years using the straight-line method.
The Company adheres to FASB ASC 360, Property, Plant, and Equipment and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. For long-lived assets, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its fair value less costs to sell. There were
Lease liabilities
The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), lease liabilities, and lease liabilities – related party. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and exclude lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet.
Revenue Recognition
The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers (“ASC 606”). Patient service revenue is recognized as performance obligations are satisfied, which occurs over time as patients simultaneously receive and consume services. Each treatment or visit generally represents a separate contract. Procedural services (e.g., ketamine infusions, esketamine administration, TMS sessions, SGB/epidural procedures) are recognized at the point in time when rendered; therapy and medication management services are recognized as sessions occur. The transaction price includes variable consideration such as contractual adjustments, expected denials, and implicit price concessions, which are estimated and constrained to amounts not expected to reverse. The Company applies the portfolio approach for contracts with similar characteristics by payer and service type. The Company elected the practical expedient not to assess a significant financing component because the period between service and payment is one year or less. The Company acts as principal in its patient service arrangements and records revenue on a gross basis.
Patient service revenue is primarily derived from services rendered to patients for outpatient behavioral health care, interventional psychiatry, and pain management procedures. The Company’s services have no fixed duration and can generally be terminated by the patient or the Company at any time; therefore, each treatment or visit is considered its own stand-alone contract.
The Company disaggregates patient service revenue from contracts with customers by service type including procedural services and therapy services and by payor type including commercial insurance, Medicare, and self-pay. Management believes this presentation best reflects the nature, amount, timing, and uncertainty of the Company’s patient service revenue and cash flows.
Cost of Patient Services
Cost of patient services includes direct costs associated with providing healthcare services, such as salaries and benefits for clinical personnel, medical supplies, pharmaceuticals, and other costs directly attributable to patient care. These costs are expensed as incurred.
Research and Development Costs
Research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.
Non-Cancellable Contracts
The Company may record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs may be recorded as a deferred cost asset.
Stock-Based Compensation
The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s common stock on the date of issuance. All stock-based compensation costs are recorded in selling, general and administrative or research and development expenses in the consolidated statements of operations based upon the underlying individual’s role at the Company.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and FASB ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company generally determines fair value of the common stock warrants using a Black-Scholes valuation methodology.
A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.
Preferred Stock
In accordance with ASC 480, the Company’s Series A preferred stock was classified as permanent equity as it was not mandatorily redeemable upon an event that is considered outside of the Company’s control. Further, in accordance with ASC 815-40, Derivatives and Hedging – Contracts in an Entity’s Own Equity, the Series A preferred stock did not meet any of the criteria that would preclude equity classification. The Company concluded that the Series A preferred stock was more akin to an equity-type instrument than a debt-type instrument, therefore the conversion features associated with the convertible preferred stock were deemed to be clearly and closely related to the host instrument and were not bifurcated as a derivative under ASC 815.
Segment Information
The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer, who reviews financial information presented for purposes of making operating decisions, assessing financial performance, and allocating resources. The Company operates through two reportable segments: (i) a pharmaceutical development segment focused on the research and development of novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia, and (ii) a clinical services segment that generates patient service revenue through the Company’s clinical operations. The CODM evaluates the operating results and financial performance of each segment separately for purposes of resource allocation and performance assessment. See Note 14 for further information.
Equity Method Investments
Investments in entities over which the Company has the ability to exercise significant influence, but does not control, are accounted for under the equity method of accounting in accordance with ASC Topic 323, Investments — Equity Method and Joint Ventures (“ASC 323”). Under the equity method, investments are initially recorded at cost and subsequently adjusted to reflect the Company’s proportionate share of the investee’s net income or loss, which is recorded in equity method income (loss) in the statements of operations. Distributions received from investees reduce the carrying amount of the investment. The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of the investment may not be recoverable.
Government Grants
The Company accounts for government grants in accordance with FASB ASC Topic 832, Government Grants. A government grant is a transfer of a monetary or tangible nonmonetary asset from a government to the Company that is not an exchange transaction. The Company recognizes a government grant when it is probable that the Company will comply with the conditions attached to the grant and that the grant will be received.
Grants related to income are recognized in earnings on a systematic and rational basis over the periods in which the Company recognizes as expense the qualifying costs the grant is intended to compensate. Grant income recognized in excess of amounts billed is recorded as a grant receivable. Amounts received before the related costs are incurred are recorded as deferred grant income. Grants related to income are presented as grant income within other income (expense), net, and the related research and development costs are presented gross.
Income Taxes
Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to be recovered or settled. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Loss Per Share
The Company applies the two-class method when computing net income or loss per share attributable to common stockholders. In determining net income or loss attributable to common stockholders, the two-class method requires income or loss allocable to participating securities for the period to be allocated between common and participating securities based on their respective rights to share in the earnings as if all of the income or loss allocable for the period had been distributed. In periods of net loss, there is no allocation required under the two-class method as the participating securities do not have an obligation to fund the losses of the Company.
Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, common stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss.
The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share attributable to common stock for the periods in which a net loss is presented because their effect would have been anti-dilutive.
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Stock options | ||||||||
| common stock warrants | ||||||||
| Unvested Restricted Stock awards | ||||||||
| common stock issuable upon conversion of Anson Notes | ||||||||
| Totals | ||||||||
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.
In December 2025, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. ASU 2025-10 establishes guidance on the recognition, measurement, and presentation of government grants received by business entities. Under ASU 2025-10, a government grant is not recognized until it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. ASU 2025-10 is effective for public business entities for annual periods beginning after December 15, 2028, and interim periods within those annual periods, with early adoption permitted. The Company early adopted ASU 2025-10 during the three months ended September 30, 2026, effective as of January 1, 2026, using the modified prospective transition method. The Company had no government grants prior to entering into the DARPA Agreement described in Note 19, so adoption had no impact on the Company’s condensed consolidated financial statements for prior periods or on opening accumulated deficit.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) and in January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization, as applicable, included in certain expense captions in the Consolidated Statements of Operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. The Company is currently evaluating the impact of adopting of ASU 2024-03.
Note 3. Revenue and accounts receivable
Revenue for the three and nine months ended September 30, 2026 is derived from services rendered to patients for outpatient behavioral health care, interventional psychiatry, and pain management procedures. The Company’s services have no fixed duration and can generally be terminated by the patient or the Company at any time; therefore, each treatment or visit is considered its own stand-alone contract.
The Company disaggregates revenue from contracts with customers by service type and by payor, as management believes this best depicts the nature, amount, timing, and uncertainty of revenue and cash flows.
Revenue by Service Type (in thousands):
| For the three months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Procedures income | $ | $ | ||||||
| Therapy services | ||||||||
| Total net patient service revenue | $ | $ | ||||||
| For the nine months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Procedures income | $ | $ | ||||||
| Therapy services | ||||||||
| Total net patient service revenue | $ | $ | ||||||
Revenue by payor (in thousands):
| For the three months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Commercial Insurance | $ | $ | ||||||
| Medicare | ||||||||
| Self-Pay | ||||||||
| Total net patient service revenue | $ | $ | ||||||
| For the nine months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Commercial Insurance | $ | $ | ||||||
| Medicare | ||||||||
| Self-Pay | ||||||||
| Total net patient service revenue | $ | $ | ||||||
The Company receives payments from the following sources: (i) commercial insurers; (ii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (CMS) and other programs; (iii) state governments under Medicaid and related programs; and (iv) individual patients and clients.
The Company determines the transaction price based on established billing rates reduced by contractual adjustments, discounts, and implicit price concessions, which represent amounts the Company does not expect to collect based on historical experience and other relevant factors. Contractual adjustments and discounts are based on contractual agreements with commercial insurance and Medicare, discount policies, and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s services have contracts containing variable considerations, such as contractual adjustments, discounts, and implicit price concessions, which are estimated and reflected as reductions to revenue in the period the services are provided. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company includes the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as credit loss expense, which is included in other operating expenses.
The Company derives a significant portion of its revenue from Medicare, and other payors that receive discounts from established billing rates. The Medicare regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided. Management estimates the transaction price on a payor specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates.
Accounts Receivable and allowance for credit loss
Accounts Receivable (in thousands):
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Accounts receivable, gross | $ | $ | ||||||
| Less: allowance for credit losses | ( | ) | ( | ) | ||||
| Accounts receivable, net | $ | $ | ||||||
Allowance for credit losses roll-forward (in thousands):
| Beginning balance as of December 31, 2025 | $ | |||
| Provision (recovery) for expected credit losses | ||||
| Write-offs, net of recoveries | ||||
| Ending Balance as of September 30, 2026 | $ |
Accounts Receivable by payor (in thousands):
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Commercial insurance | $ | $ | ||||||
| Medicare | ||||||||
| Self-pay | ||||||||
| Accounts receivable, gross | $ | $ | ||||||
Estimation inputs and credit quality information (summary):
| ● | Receivables are pooled by payer class and aging; loss rates reflect historical experience updated for current conditions and reasonable and supportable forecasts with reversion to long‑run averages beyond the forecast horizon. The Company does not suspend recognition of revenue on a “nonaccrual” basis for trade receivables. |
Note 4. Prepaid expense and other current assets
Prepaid expense and other current assets consisted of the following at the dates indicated (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| Prepaid expense and other current assets: | ||||||||
| Prepaid insurance | $ | $ | ||||||
| Prepaid clinical development costs | ||||||||
| Other prepaid expense | ||||||||
| Total prepaid expense and other current assets | $ | $ | ||||||
Note 5. Property and equipment, net
As of September 30, 2026 and December 31, 2025, property and equipment, net, consisted of the following (in thousands):
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Medical equipment | $ | $ | ||||||
| Computer equipment | ||||||||
| Aircraft | ||||||||
| Furniture and fixtures | ||||||||
| Leasehold improvement | ||||||||
| Total property and equipment | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Depreciation expense was less than $
Note 6. Leases
The Company has operating leases for three healthcare clinics in Naples, Fort Myers, and West Palm Beach, Florida and operating leases for certain medical equipment:
| ● | Naples Lease (Related Party): The Company leases its Naples clinic from Dura Properties, LLC, an entity owned and controlled by Dura’s former sole member prior to the acquisition. Following the acquisition on September 8, 2025, the former member became a minority member in HTX Management Company LLC, which interests are convertible into a minority position of Hope Therapeutics, Inc. at the sole discretion of the holder. Right-of-use (“ROU”) assets and operating lease liabilities was measured under ASC 805 as if the leases were new at the acquisition date. The amended lease commenced on September 8, 2025 and expires on December 31, 2027. It is non-cancelable and requires monthly base rent of $ |
| ● | Fort Myers Lease (Third Party): The Company amended a lease for its Fort Myers clinic on September 8, 2025, with a commencement date of September 8, 2025, and an expiration date of November 30, 2029. ROU assets and operating lease liabilities were measured under ASC 805 as if the leases were new at the acquisition date. The amended lease is non-cancellable and requires monthly base rent of $ |
| ● | West Palm Beach Lease (Third Party): On November 14, 2025, the Company entered into a sublease agreement with Third Party of office space located at West Palm Beach, Florida. The sublease commenced on December 1, 2025 and expires on April 5, 2028. The sublease provides for fixed annual rent of approximately $ |
| ● | Medical Equipment Leases (Third Party): On January 7, 2026, the Company entered into |
The components of lease expense included in the Company’s statement of operations were as follows (in thousands):
| For the three | For the nine | ||||||||
| months | months | ||||||||
| ended | ended | ||||||||
| September 30, | September 30, | ||||||||
| Expense Classification | 2026 | 2026 | |||||||
| Operating lease expense: | |||||||||
| Amortization of ROU asset | Selling, general and administrative | $ | $ | ||||||
| Accretion of operating lease liability | Selling, general and administrative | ||||||||
| Amortization of ROU asset - related party | Selling, general and administrative | ||||||||
| Accretion of operating lease liability - related party | Selling, general and administrative | ||||||||
| Total operating lease expense | $ | $ | |||||||
Other information related to leases is as follows:
| As of September 30, | As of December 31, | |||||||
| 2026 | 2025 | |||||||
| Weighted-average remaining lease term: | ||||||||
| Operating leases (in years) | ||||||||
| Weighted-average discount rate: | ||||||||
| Operating leases | % | % | ||||||
The future minimum lease payments required under leases as of September 30, 2026 were as follows (in thousands):
| Fiscal Year | ||||
| Remainder of 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Total | ||||
| Less: imputed interest | ( | ) | ||
| Lease liability | $ |
Note 7. Accrued and other current liabilities
Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| Accrued and other current liabilities: | ||||||||
| Refund liability (see Note 8) | $ | $ | ||||||
| Professional services | ||||||||
| Employee costs | ||||||||
| Accrued research and development expense | ||||||||
| Accrued Dura acquisition cost due post-closing | ||||||||
| Other accrued expense | ||||||||
| Total accrued and other current liabilities | $ | $ | ||||||
Note 8. Alvogen licensing agreement
In June 2023, the Company entered into a License Agreement with Alvogen. On June 21, 2024, the Company received a notice of termination from Alvogen effective immediately. Following the termination of the License Agreement by Alvogen, the amounts advanced pursuant to the amendment became due and payable to Alvogen. Accordingly, the refund liability has not been reclassified to deferred revenue or recorded as revenue as of September 30, 2026 and will remain permanent as refund liability until settled.
Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination. In accordance with the License Agreement, any unpaid amounts accrue interest from the due date at a rate equal to one‑month Term SOFR plus
Note 9. Debt
Anson Convertible Promissory Notes (the “Anson Notes”)
On August 12, 2024, the Company entered into the Anson Purchase Agreement with the Anson Investment Master Fund LP and Anson East Master Fund LP (collectively “Anson”). The Company agreed to sell, in three equal tranches, original issue discount Anson Notes in the aggregate principal amount of up to approximately $
On August 14, 2024, the Company entered into the first tranche Senior Secured Convertible Note Agreements (the “First Tranche Notes”) with Anson at various amounts for an aggregate of $
Pursuant to the Anson Purchase Agreement, on October 10, 2024 (the “Second Closing Date”), the Company sold a total of $
Pursuant to the Anson Purchase Agreement, on January 28, 2025 (the “Third Closing Date”), the Company sold a total of $
During the year ended December 31, 2024, Anson converted $
During the three months ended March 31, 2025, Anson converted $
During the remainder of the year ended December 31, 2025, Anson converted the remaining $
No Anson Notes remained outstanding as of September 30, 2026 and December 31, 2025.
Due to the embedded features within the Anson Notes, the Company elected to account for the First, Second, and Third Tranche Notes at fair value at inception. Subsequent changes in fair value were recorded as a component of other income (loss) in the consolidated statements of operations. During the three and nine months ended September 30, 2025, the Company recorded a loss from the change in fair value of the Second and Third Tranche Notes of $
On or about January 27, 2025, the Company and Anson entered into a Consent and Waiver Agreement (the “CWA”), relating to certain rights and prohibitions arising under the Anson Purchase Agreement and the Notes. In the CWA, Anson provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the Anson Purchase Agreement and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and Anson dated August 14, 2024, until March 31, 2025. On March 20, 2025, following the conversion of less than $
In connection with the Second RD Purchase Agreement (see Note 11), and pursuant to the full ratchet anti-dilution provisions contained in the Anson financing agreements, the exercise price of all outstanding common stock purchase warrants issued on August 14, 2024, October 10, 2024, January 28, 2025, and January 29, 2025 (collectively, the “Anson Warrants”) were each adjusted to $
The holders of Anson Notes and Anson Warrants, in accordance with an agreement entered into with Anson on September 30, 2025, agreed to, among other things, i) certain trading volume limitations, and ii) a partial exercise on previously issued Anson Warrants for cash. Specifically, if the closing stock price of the Company’s common stock as reported on the Principal Market (as defined in the August 2024 Purchase Agreement) is below $
The following table presents the Anson Notes as of December 31, 2025 (in thousands):
| December 31, | ||||
| 2025 | ||||
| Par value of the Anson Notes | $ | |||
| Initial original issue discount | ( | ) | ||
| Conversions and repayments of principal and interest (shares) | ( | ) | ||
| Carrying value of the Anson Notes before current period change in fair value | ( | ) | ||
| Fair value allocated to common stock liability classified warrants | ( | ) | ||
| Fair value adjustment through earnings | ||||
| Total carrying value of Anson Notes | $ | |||
| Convertible note payable - current portion | $ | |||
| Convertible note payable, net of current portion | $ | |||
Note 10. Commitments and contingencies
Sarah Herzog Memorial Hospital License Agreement
The Company is required to make certain payments related to the development of NRX-101 (the “Licensed Product”) in order to maintain the license agreement (the “SHMH License Agreement”) with the Sarah Herzog Memorial Hospital Ezrat Nashim (”Licensor”).
In April 2025, the Company and the Licensor entered into an Amendment to the SHMH License Agreement (the “Amendment”), which resolved a dispute between the parties and modified certain payment and reporting terms of the License Agreement. The Amendment also modified certain milestone obligations related to NRX‑101. In full satisfaction of the milestone payments associated with the completion of Phase II and Phase III clinical trials for NRX‑101, the Company is required to pay the Licensor a single milestone payment of $
Milestone Payments
| End of Phase I Clinical Trials of Licensed Product (completed) | $ | |||
| End of Phase II Clinical Trials of Licensed Product (completed) | $ | |||
| End of Phase III Clinical Trials of Licensed Product | $ | |||
| First Commercial Sale of Licensed Product in U.S. | $ | |||
| First Commercial Sale of Licensed Product in Europe | $ | |||
| Annual Revenues Reach $100,000,000 | $ |
The milestone payments due above may be reduced by
Royalties
A royalty in an amount equal to: (a)
Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of
Annual Maintenance Fee
A fixed amount of $
Beginning with the sixth anniversary of the effective date of the License Agreement (or April 16, 2025), future annual license maintenance fees of $
On May 31, 2026, the Company issued
Exclusive License Agreement
In 2023, the Company entered into a license agreement with Apkarian Technologies LLC to in-license U.S. patent 8,653,120 that claims the use of DCS for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. For the three and nine months ended September 30, 2026 and 2025, the Company has recorded
Kadima Purchase Agreement
On May 9, 2025, HOPE and its majority-owned subsidiary, HTX, entered into an Asset Purchase and Contribution Agreement (the “Kadima Purchase Agreement”), with Kadima Medical, Kadima Holdings, Inc. (“Kadima Holdings”), and David Feifel, M.D., PH.D (“Feifel”, and collectively with Kadima Medical and Kadima Holdings, “Kadima”), pursuant to which the Company agreed to purchase and Kadima agreed to sell, certain assets of Kadima, subject to the satisfaction of certain closing conditions (the “Acquisition”).
The Kadima Purchase Agreement contains representations, warranties and covenants of the Company and Kadima that are customary for a transaction of this nature, including among others, covenants by Kadima regarding the validity of certain material contracts entered into between Kadima and third-parties being assigned to the Subsidiaries, title to the assets being sold by Kadima, the condition and sufficiency of the assets being purchased, and Kadima’s rights to its intellectual property, tax liabilities, and the investment representations of Kadima.
The Kadima Purchase Agreement also contains customary indemnification provisions whereby Kadima will indemnify the Company for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of Kadima, pre-closing taxes of Kadima, and certain other matters, subject to certain caps and thresholds.
As of the date of this Report, the Acquisition has not been consummated.
On May 15, 2026, Kadima Neuropsychiatry Institute, Medical Corp. and David Feifel, M.D., Ph.D. filed a complaint against the Company, HTX and HOPE in the Superior Court of California, County of San Diego, seeking specific performance compelling the defendants to consummate the transactions contemplated by the Kadima Purchase Agreement and alleging breach of contract and misrepresentation in connection with the Kadima Purchase Agreement. On July 29, 2026, the Company removed the action to the U.S. District Court for the Southern District of California (Case No. 3:26-cv-04359-WQH-JAC) alleging that Kadima failed to meet critical conditions of closing. The complaint is under seal. Based on the information currently available, the Company does not believe that the ultimate resolution of these proceedings will have a material adverse effect on its financial condition or results of operations.
Operating Lease
The Company leases office space on a month-to-month basis. The rent expense for the three months ended September 30, 2026 and 2025 was $
The Company also leases three healthcare clinical facilities and office space located in Naples, West Palm Beach and Fort Myers, Florida and certain medical equipment under non-cancelable operating lease agreements. Details regarding lease terms, future minimum lease payments, and right-of-use assets and liabilities are disclosed in Note 6.
Legal Proceedings
The Company is, from time to time, involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of nearly all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. Other than the Kadima matters described above, there are no material pending or threatened legal proceedings at this time.
Note 11. Equity
Preferred Stock
Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has 50,000,000 shares of preferred stock authorized with a par value of $
Common stock
Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized
ATM Purchase Agreements
From February 20, 2024 to July 29, 2024, the Company announced that it entered into multiple at-the-market purchase agreements (the “ATM Purchase Agreements”) subject to standard closing conditions where accredited investors purchased
During the three and nine months ended September 30, 2025, the aggregate net cash proceeds to the Company from the ATM Purchase Agreements were approximately $
2026 Underwritten Public Offering
On June 4, 2026, the Company completed an underwritten public offering of
2026 common stock Issued for Services
On May 31, 2026, the Company issued an aggregate of
2025 Securities Purchase Agreement
On January 27, 2025, the Company entered into a securities purchase agreement (the “First RD Purchase Agreement”) with Anson for the sale by the Company of
On March 20, 2025, following the conversion of less than $
As previously mentioned, during the year ended December 31, 2025, Anson converted the remaining $
Warrants
Substitute Warrants – Liability
On May 24, 2021, the Company completed the merger (“Merger”) under the Agreement and Plan of Merger dated December 13, 2020, as amended, among the Company (formerly Big Rock Partners Acquisition Corp.), NeuroRx, Inc., and Big Rock Merger Corp., a wholly owned subsidiary of our company. In the transaction, Big Rock Merger Corp. merged with and into NeuroRx, with NeuroRx continuing as the surviving entity. In connection with the Merger in 2021, each warrant to purchase shares of common stock of NRx that was outstanding and unexercised immediately prior to the effective time (whether vested or unvested) was assumed by Big Rock Partners Acquisition Corp. (BRPA) and converted into a warrant, based on the exchange ratio (of
Assumed Public Warrants – Equity
Prior to the Merger, the Company had warrants outstanding (the “Public Warrants”) to purchase up to
During the fiscal years ended December 31, 2025 and 2024
Assumed Private Placement Warrants – Liabilities
Prior to the Merger, the Company had outstanding Private Placement Warrants (the “Private Placement Warrants”) to purchase up to
See Note 13 for discussion of the fair value measurement of the Company’s warrant liabilities.
Warrants – Equity
As discussed above, on February 29, 2024, in conjunction with the sale of
On February 28, 2024, the Company issued to the underwriters
On March 5, 2024, the Company issued underwriter’s warrants to purchase up to
On April 19, 2024, the Company issued to underwriter’s
On May 23, 2024, the Company issued underwriter’s warrants to purchase up to
Alvogen Warrants – Equity
In conjunction with the amended Licensing Agreement with Alvogen discussed in Note 8, on February 7, 2024 the Company issued warrants to purchase up to
Anson Warrants – Liability
The Anson Warrants, originally issued in the Anson Purchase Agreement, are recognized as derivative liabilities in accordance with ASC 815, as certain settlement features included in the Anson Warrants are not indexed to the Company's own stock, and therefore preclude equity classification. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period, and any change in fair value is recognized in the Company’s consolidated statements of operations. The Anson Warrants are measured at fair value using a Black-Scholes model, and all warrant liabilities are classified as current liabilities on the Company's consolidated balance sheets.
On August 14, 2024, in conjunction with the issuance of the First Tranche Notes, the Company issued
On October 10, 2024, in conjunction with the issuance of the Second Tranche Notes, the Company issued
On January 28, 2025, in conjunction with the issuance of the Third Tranche Notes, the Company issued warrants to purchase up to
In 2025, in connection with the Second RD Purchase Agreement, and pursuant to the full ratchet anti-dilution provisions contained in the Anson financing agreements, the exercise price of all Anson Warrants were each adjusted to $
The holders of Anson Notes and Anson Warrants, in accordance with an agreement entered into with Anson on September 30, 2025, agreed to, among other things, i) certain trading volume limitations, and ii) a partial exercise of previously issued Anson Warrants for cash. Specifically, if the closing stock price of the Company’s common stock as reported on the Principal Market (as defined in the August 2024 Purchase Agreement) is below $3.25 on any trading day, Anson may not sell, dispose of, or otherwise transfer, in the aggregate, more than 12.5% of the composite daily trading volume of the Company’s common stock on that trading day. In accordance with the agreement,
RD Warrants – Liabilities
As discussed above, on January 29, 2025, in conjunction with the issuance of the First RD Shares, the Company issued the First RD Warrants to purchase up to
Consideration Warrants – Liability
As discussed above, on March 20, 2025, in conjunction with the issuance of the Consideration Shares, the Company issued Consideration Warrants to purchase up to
As of September 30, 2026, the aggregate fair value of all liability classified warrants, which include Substitute Warrants, Assumed Private Placement Warrants, Anson Warrants, First RD Warrants and Consideration Warrants, was $
The following table provides the activity for all warrants for the respective periods.
| Aggregate | ||||||||||||||||
| Weighted | Weighted | Intrinsic | ||||||||||||||
| Average | Average | Value | ||||||||||||||
| Total Warrants | Remaining Term | Exercise Price | (in thousands) | |||||||||||||
| Outstanding as of December 31, 2024 | $ | $ | ||||||||||||||
| Issued | — | |||||||||||||||
| Exercised | ( | ) | — | |||||||||||||
| Expired | ( | ) | — | — | — | |||||||||||
| Outstanding as of December 31, 2025 | $ | $ | ||||||||||||||
| Issued | — | — | ||||||||||||||
| Exercised | — | — | ||||||||||||||
| Expired | — | — | — | |||||||||||||
| Outstanding as of March 31, 2026 | $ | $ | ||||||||||||||
| Issued | — | — | ||||||||||||||
| Exercised | ( | ) | — | — | ||||||||||||
| Expired | ( | ) | — | — | ||||||||||||
| Outstanding as of June 30, 2026 | $ | |||||||||||||||
| Issued | — | — | ||||||||||||||
| Exercised | — | — | ||||||||||||||
| Expired | — | — | ||||||||||||||
| Outstanding as of September 30, 2026 | $ | |||||||||||||||
Note 12. Stock-based compensation
2016 Omnibus Incentive Plan
Prior to the Merger, the Company maintained its 2016 Omnibus Incentive Plan (the “2016 Plan”), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of common stock that were subject to awards and issuable under the 2016 Plan was
In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of common stock at an adjusted exercise price per share, based on the Exchange Ratio (of 0.316:1).
Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate
2021 Omnibus Incentive Plan
The Company’s 2021 Omnibus Incentive Plan (the “2021 Plan”) permits the granting of incentive stock options, restricted stock awards, other stock-based awards or other cash-based awards to employees, directors, and non-employee consultants. On December 28, 2023, the first amendment to the 2021 Plan was executed which increased the maximum number of shares (i) available for issuance under the Plan by an additional
Option Awards
The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is
On January 1, 2026, the Company issued
On January 27, 2026, the Company issued
On May 31, 2026, the Company issued
The stock options granted during the three months ended September 30, 2026 were valued utilizing the Black-Scholes options pricing model with the following inputs: $
The stock options granted during the nine months ended September 30, 2026 were valued utilizing the Black-Scholes options pricing model with the following inputs: $
The following table summarizes the Company’s employee and non-employee stock option activity under the 2021 Plan for the following periods:
| Weighted | ||||||||||||||||
| average | ||||||||||||||||
| Weighted | remaining | Aggregate | ||||||||||||||
| average | contractual | intrinsic | ||||||||||||||
| Number of | exercise | life (in | value (in | |||||||||||||
| shares | price | years) | thousands) | |||||||||||||
| Outstanding as of December 31, 2024 | ||||||||||||||||
| Options granted | ||||||||||||||||
| Forfeited/Expired | ( | ) | — | — | ||||||||||||
| Outstanding as of December 31, 2025 | $ | $ | ||||||||||||||
| Options granted | — | |||||||||||||||
| Forfeited/Expired | ( | ) | — | — | ||||||||||||
| Outstanding as of March 31, 2026 | $ | $ | ||||||||||||||
| Options granted | — | — | ||||||||||||||
| Forfeited/Expired | ( | ) | ( | ) | — | — | ||||||||||
| Outstanding as of June 30, 2026 | $ | |||||||||||||||
| Options granted | — | — | ||||||||||||||
| Forfeited/Expired | — | — | ||||||||||||||
| Outstanding as of September 30, 2026 | $ | $ | ||||||||||||||
| Options vested and exercisable as of September 30, 2026 | $ | $ | ||||||||||||||
Stock-based compensation expense related to stock options was $
At September 30, 2026, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $
Restricted Stock Awards
The following table presents the Company’s Restricted Stock Activity:
| Weighted | ||||||||
| Average Grant | ||||||||
| Date Fair | ||||||||
| Awards | Value | |||||||
| Balance as of December 31, 2024 (unvested) | ||||||||
| Granted | $ | |||||||
| Vested | $ | |||||||
| Forfeited | $ | |||||||
| Balance as of December 31, 2025 (unvested) | $ | |||||||
| Granted | $ | |||||||
| Vested | $ | |||||||
| Forfeited | $ | |||||||
| Balance as of March 31, 2026 | $ | |||||||
| Granted | $ | |||||||
| Vested | ( | ) | $ | ( | ) | |||
| Forfeited | $ | |||||||
| Balance as of June 30, 2026 | $ | |||||||
| Granted | $ | |||||||
| Vested | $ | |||||||
| Forfeited | $ | |||||||
| Balance as of September 30, 2026 | $ | |||||||
On October 22, 2025, the Company granted
On May 31, 2026, the Company granted
On July 28, 2026, the Company granted
Stock-based compensation expense related to RSAs was approximately $0.1 million for the three and nine months ended September 30, 2026.
The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands):
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Stock-based compensation expense | ||||||||||||||||
| Selling, general and administrative | $ | $ | $ | $ | ||||||||||||
| Research and development | ||||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | $ | ||||||||||||
Note 13. Fair value measurements
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2026 and December 31, 2025 and during the three and nine months ended September 30, 2026 and 2025. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of stock options and warrants issued for services, and warrants issued with the Convertible Notes are estimated based on the Black-Scholes model. The fair value of the convertible notes payable was estimated utilizing a Monte Carlo simulation.
Fair Value on a Recurring Basis
The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level 1 measurement. The estimated fair value of the warrant liabilities and convertible note payable represent Level 3 measurements. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at September 30, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):
| Description | Level | September 30, 2026 | December 31, 2025 | |||||||||
| Assets: | ||||||||||||
| Money Market Account | 1 | $ | $ | |||||||||
| Liabilities: | ||||||||||||
| Warrant liabilities (Note 11) | 3 | $ | $ | |||||||||
Convertible Note Payable - Anson
The significant inputs used in the Monte Carlo simulation to measure the Anson Convertible Notes that are categorized within Level 3 of the fair value hierarchy are as follows:
| September 30, | |||||
| 2025 | |||||
| Stock price on valuation date | $ | ||||
| Time to expiration | – | ||||
| Notes market interest rate | |||||
| Equity volatility | 117.5% | – | 138.0% | ||
| Risk-free rate | |||||
| Probability of default | % | ||||
The following table sets forth a summary of the changes in the fair value of the Anson Notes categorized within Level 3 of the fair value hierarchy (in thousands):
| Fair value of Anson Notes as of December 31, 2024 | $ | |||
| Fair value of Anson III Note at issuance | ||||
| Conversion and repayments of principal and interest (shares) | ( | ) | ||
| Fair value adjustment through earnings | ||||
| Fair value of Anson Notes as of March 31, 2025 | ||||
| Conversion and repayments of principal and interest (shares) | ( | ) | ||
| Fair value adjustment through earnings | ||||
| Fair value of Anson Notes as of June 30, 2025 | $ | |||
| Conversion and repayments of principal and interest (shares) | ( | ) | ||
| Fair value adjustment through earnings | ||||
| Fair value of Anson Notes as of September 30, 2025 | $ |
During the nine months ended September 30, 2025, the Company converted the remaining outstanding principal of the Anson Notes, together with accrued interest, with an aggregate carrying amount of $
Warrant Liabilities
The Company utilizes a Black-Scholes model approach to value its liability-classified warrants at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liabilities is determined using Level 3 inputs. There were
The weighted-average significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 of the fair value hierarchy are as follows:
| September 30, 2026 | December 31, 2025 | ||||||||
| Stock price on valuation date | $ | $ | |||||||
| Exercise price per share | $ | – | $ | - | $ | ||||
| Expected life | – | - | |||||||
| Volatility | – | 107.99% | 80.52 | - | 118.80% | ||||
| Risk-free rate | 5.00% | 3.61 | - | 3.64% | |||||
| Dividend yield | |||||||||
| Fair value of warrants | $2.17 | $2.29 | $ | - | |||||
A reconciliation of warrant liabilities is included below (in thousands):
| Balance as of December 31, 2025 | $ | |||
| Change in fair value of warrant liabilities | ( | ) | ||
| Balance as of March 31, 2026 | $ | |||
| Change in fair value of warrant liabilities | ||||
| Balance as of June 30, 2026 | $ | |||
| Change in fair value of warrant liabilities | ( | ) | ||
| Balance as of September 30, 2026 | $ |
Note 14. Segment reporting
On September 8, 2025, HOPE completed the acquisition of Dura, and a revenue-generating clinical organization. Following the acquisition, the Company began generating patient service revenue through Dura’s operations. As a result, the Company now operates in two reportable segments, consistent with the manner in which the Chief Executive Officer, who is designated as the Company’s CODM, evaluates the Company’s performance and allocates resources. The Company’s operations consist of (i) the development of novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia, and (ii) the operation of a clinical services business through Hope.
The Company generated $
The CODM does not separately evaluate performance by geographic region or product line, as the Company has limited operations due to the current liquidity and funding of the Company. The Company’s operations are conducted solely within the U.S.
Significant Segment Information
All of the Company’s assets relate to these two operating segments, see the accompanying balance sheets excerpt below.
All of the Company’s operating expenses, which consist of cost of patient services, research and development, selling, general and administrative expenses, and depreciation and amortization expenses, are attributable to its two operating segments, see the accompanying statements of operations.
The following table reconciles the loss from operations to total loss for the three months ended September 30, 2026 and 2025 (in thousands):
| For the three months ended | ||||||||||||||||
| September 30, | ||||||||||||||||
| Expense Category | NRx | Dura | 2026 | 2025 | ||||||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Interest income | ( | ) | ( | ) | ( | ) | ||||||||||
| Interest expense | ||||||||||||||||
| Change in fair value of convertible notes payable | ||||||||||||||||
| Change in fair value of warrant liabilities | ( | ) | ( | ) | ||||||||||||
| Loss on convertible note conversions | ||||||||||||||||
| Gain on exercise of warrants | ( | ) | ||||||||||||||
| Income from equity method investments | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
The following table reconciles the loss from operations to total loss for the nine months ended September 30, 2026 and 2025 (in thousands):
| For the nine months ended | ||||||||||||||||
| September 30, | ||||||||||||||||
| Expense Category | NRx | Dura | 2026 | 2025 | ||||||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Interest income | ( | ) | ( | ) | ( | ) | ||||||||||
| Interest expense | ||||||||||||||||
| Change in fair value of convertible notes payable | ||||||||||||||||
| Change in fair value of warrant liabilities | ||||||||||||||||
| Loss on issuance of Registered Direct Offering | ||||||||||||||||
| Loss on Consideration Shares and Warrants | ||||||||||||||||
| Loss on convertible note conversions | ||||||||||||||||
| Gain on exercise of warrants | ( | ) | ||||||||||||||
| Income from equity method investments | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
Long-lived assets consist of property, furniture and equipment which are included in property and equipment, net in the balance sheet. Long-lived assets by year are as follows (in thousands):
| As of | ||||||||||||||||
| NRx | Dura | September 30, 2026 | December 31, 2025 | |||||||||||||
| Medical equipment | $ | $ | $ | $ | ||||||||||||
| Computer equipment | ||||||||||||||||
| Aircraft | ||||||||||||||||
| Furniture and fixtures | ||||||||||||||||
| Leasehold improvements | ||||||||||||||||
| Total property and equipment | $ | $ | $ | $ | ||||||||||||
| Less: Accumulated depreciation | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Property and equipment, net | $ | $ | $ | $ | ||||||||||||
Note 15. Income taxes
The Company recorded
For all periods presented, the pretax losses incurred by the Company received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.
The Company has no open tax audits with any taxing authority as of September 30, 2026.
Note 16. Business acquisitions
Dura Medical, LLC
Transaction Overview
On September 8, 2025, HOPE, a majority owned subsidiary the Company, completed the acquisition of Dura, a Florida-based behavioral health and interventional psychiatry practice with locations in Naples and Fort Myers, Florida. Dura was founded in 2018 and provides outpatient mental health treatment specializing in evidence-based therapies for treatment-resistant conditions, including depression, anxiety, PTSD, OCD, and chronic pain. Services include ketamine infusion therapy, Spravato® administration, TMS, Stellate Ganglion Blocks, psychotherapy, and medication management.
The acquisition aligns with the Company’s strategy to expand its clinical care delivery platform through HOPE and establish a multi-site network offering advanced interventional psychiatry services. Management expects the acquisition to accelerate revenue generation and provide a foundation for integrating proprietary therapeutics, including NRX-100 and NRX-101, upon FDA approval.
Consideration Transferred
The fair value of the consideration transferred was $
The following items were determined to represent post-employment compensation under ASC 805 and ASC 718 and are excluded from the purchase price consideration:
| ● | Issuance of |
| ● | Contingent consideration of up to $ |
These amounts will be accounted for as compensation expense in future periods as services are rendered.
In connection with the acquisition of Dura, the Company incurred total acquisition-related costs of approximately $
Purchase Price Allocation
The Company has applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired, and liabilities assumed at their fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. As the Company finalizes the estimation of the fair value of the purchase price and the fair value of the assets acquired and liabilities assumed, additional adjustments may be recorded during the measurement period (a period not to exceed 12 months from the acquisition date).
The Company recorded all tangible and identifiable intangible assets acquired and liabilities assumed at their fair values as of the acquisition date. The measurement period ended September 8, 2026, and the purchase price allocation is final. The allocation is as follows:
| Amount Recognized as of the Acquisition Date (In Thousands) | ||||
| Assets assumed | ||||
| Cash and cash equivalents | $ | |||
| Accounts receivable | ||||
| Other current and non-current assets | ||||
| Customer relationship | ||||
| Trade name | ||||
| Goodwill | ||||
| Total assets acquired | ||||
| Less: liabilities assumed | ( | ) | ||
| Net assets acquired | $ |
Certain adjustments of approximately $
Intangible Assets
The Company identified the following finite-lived intangible assets, which will be amortized on a straight-line basis over their estimated useful lives once finalized:
| ● | Trade Name – includes the “Dura Medical” name and associated trademarks. |
| ● | Customer relationship – representing the value of established patient relationships and referral sources. |
The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands):
| Weighted Average | ||||||||
| Useful Life | ||||||||
| Fair Values | (Years) | |||||||
| Trade name and trademarks | $ | |||||||
| Customer relationships | ||||||||
| Total intangible assets | ||||||||
| Less accumulated amortization | ( | ) | ||||||
| Net carry value | $ | |||||||
The Company incurred amortization expense of $
As of September 30, 2026, the maturities of the Company’s intangible assets were as follows (in thousands):
| Remainder of 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total | $ |
Goodwill
Goodwill of approximately $
Measurement Period
The Acquisition was recorded as a business combination on a preliminary valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). We expect to complete our purchase price allocation, as well as our fair value estimate of the purchase price consideration as soon as reasonably possible, not to exceed one year from the acquisition date. Adjustments to the preliminary purchase price and allocation could be material. Goodwill and intangible assets represent the excess of the purchase price consideration over the preliminary valuation of the other net assets acquired.
Pro-Forma Financial Information (Unaudited)
The following unaudited pro forma information presents the consolidated results of Dura included in the Company’s consolidated statement of operations loss for the three and nine months ended September 30, 2025, as if the acquisition was made on January 1, 2025. The unaudited pro forma information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods, or the results of operations that actually would have been realized had the entities been a single company during the periods presented or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of the companies.
The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on January 1, 2025, is as follows (in thousands):
| (Unaudited) | (Unaudited) | |||||||
| For the three months ended | For the nine months ended | |||||||
| September 30, 2026 | September 30, 2026 | |||||||
| Revenue | $ | $ | ||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
The unaudited pro forma results for the three and nine ended September 30, 2025, include material nonrecurring adjustments of $
Note 17. Related party transactions
Glytech Agreement
The Company licenses patents that are owned by Glytech, LLC (“Glytech”), pursuant to a license agreement (the “Glytech Agreement”). Glytech is owned by Daniel Javitt, the co-founder and a former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to the Company. During the three months ended September 30, 2026 and 2025, the Company paid Glytech $
The Fourth Amendment to the Glytech Agreement, effective as of December 31, 2020, includes an equity value-triggered transfer of Excluded Technology from Glytech to the Company. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do not recite either DCS or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that the Company considers “pipeline” or “future product” opportunities, which contain a combination of pharmaceutical components different from those contained in NRX-100 and NRX-101. On November 6, 2022 the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to the Company for no additional consideration at any time upon receipt of written notice from the Company if, on or prior to June 30, 2024, (i) the value of the Glytech equity holdings in the Company (the “Glytech Equity”) has an aggregate liquidity value of at least $
Consulting Agreement with Dr. Jonathan Javitt
The Chairman and Chief Executive Officer of the Company, Dr. Jonathan Javitt, is a stockholder of the Company and a member of the Board. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as chief executive officer under an employment agreement with the Company until March 8, 2022 and currently serves under a consulting agreement with the Company as Chief Executive Officer thereafter and received compensation of $
On March 29, 2023, the consulting agreement dated March 8, 2022 (the “Javitt Consulting Agreement”) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Javitt Consulting Agreement until March 8, 2024 with automatic annual renewals thereafter unless one party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $
Consulting Agreement with Zachary Javitt
Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company’s Chief Executive Officer who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of less than $
Included in accounts payable were $
Consulting Agreement with Michael Taylor
In June 2024, the Company entered into a consulting agreement with Michael Taylor (the “Taylor Consulting Agreement”), who was subsequently appointed to the Company’s Board of Directors in January 2025. Pursuant to the Taylor Consulting Agreement, Mr. Taylor provides capital formation and strategic advisory services in support of the Company’s development of HOPE, including advising on the Company’s initial funding efforts for HOPE, assisting with outreach to family offices and similar investors, and supporting the identification and retention of a brand ambassador. During the three months ended September 30, 2026 and 2025, the Company made cash payments to Mr. Taylor totaling less than $
Naples Lease Operating Agreement
The Company leases its Naples clinic from Dura Properties, LLC, an entity owned and controlled by Dura’s former sole member. Following the acquisition on September 8, 2025, the former sole member became a director and minority shareholder of the Company. As a result, the related-party lease right-of-use (“ROU”) asset and operating lease liability were measured as of the acquisition date in accordance with FASB ASC 805, Business Combinations, as if the lease were a new lease as of that date. Lease payments under the lease agreement were less than $
Note 18. Investment in Cohen and Associates
On October 17, 2025, the Company, through its subsidiary HOPE, completed the acquisition of a strategic, minority ownership interest in Cohen & Associates, LLC, a Florida limited liability company (“Cohen & Associates”), for cash consideration of $
The Company accounts for its investment in Cohen & Associates under the equity method of accounting, as the Company has the ability to exercise significant influence over Cohen & Associates but does not control the entity. The investment is recorded at cost and subsequently adjusted for the Company’s proportionate share of Cohen & Associates’ net income or loss, which is included in equity method loss in the accompanying statements of operations for the year ended December 31, 2025 in the amount of $
Note 19. Government Grants
On September 29, 2026, NRX Defense Systems, Inc., a wholly owned subsidiary of the Company, entered into an Other Transaction for Research agreement (the “DARPA Agreement”) with the Defense Advanced Research Projects Agency (“DARPA“) under 10 U.S.C. § 4021. The DARPA Agreement funds the Synaptic Plasticity Augmented Rapid Circuit Stimulation (“SPARC-TMS“) program, a pivotal, 240-patient randomized controlled trial evaluating ultra-accelerated transcranial magnetic stimulation combined with NRX-101 for the treatment of treatment-resistant depression.
The DARPA Agreement has an
In the forty-five (45) days subsequent to the signing of the contract, the Company completed the first two of ten contractual milestones and DARPA agreed to receive invoices totaling approximately $
The Company accounts for the DARPA Agreement as a government grant related to income in accordance with ASC 832, Government Grants, as amended by ASU 2025-10, which the Company early adopted effective January 1, 2026.
For the three and nine months ended September 30, 2026, the Company recognized
Note 20. Subsequent events
From October 1, 2026 through November 16, 2026, the Company sold an aggregate of
On October 15, 2026, the Company received a discipline review letter from the FDA requesting minor changes to the proposed labeling for its preservative-free ketamine ANDA. The Company has evaluated subsequent events through the date these financial statements were issued.
On October 30, 2026, the Company announced that the FDA approved the Company’s Abbreviated New Drug Application (“ANDA”) for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments (“GDUFA”).
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of NRx Pharmaceuticals’ financial condition and plan of operations together with NRx Pharmaceuticals' consolidated financial statements and the related notes appearing elsewhere herein. In addition to historical information, this discussion and analysis contains forward looking statements that involve risks, uncertainties, and assumptions. NRx Pharmaceuticals’ actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section entitled “Risk Factors” included elsewhere herein. All references to “Note,” followed by a number reference from 1 to 20 herein, refer to the applicable corresponding numbered footnotes to these consolidated financial statements.
Overview
The Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a commercial-stage bio-pharmaceutical company that controls an ecosystem of companies focused on the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (“PTSD”), ALS, Multiple Sclerosis, and schizophrenia. Over the past year, the Company has undergone substantial growth and reorganization.
The third quarter of 2026 together with the subsequent period represents a significant “sea change” in which the Company has obtained its first FDA drug approval and consequently the potential for meaningful commercial revenue, together with a US Defense Contract that offers the Company a unique commercial direction in the rapidly-growing interventional psychiatry market. In the process, the Company established a Defense Contracting subsidiary that now has the requisite security and cybersecurity clearances to broaden its defense-related business activities.
The Company completed its first public offering with the sponsorship of the B Group in June 2026. This provided funding for the completion of the ketamine ANDA, building of pharmaceutical launch stock, and recruitment of a commercial team. The first 9 months of 2026 additionally encompassed the founding of NRx Defense Systems and GeNeuro, Inc., as detailed below. The revitalization of NRx’s corporate structure has enabled key partnerships with the US National Institutes of Health, the Fondation Fondamental and the French Government, and an emerging partnership with the Canton of Basel Switzerland.
NRx is now comprised of a constellation of companies, as depicted below, that are expected to contribute to corporate value in a manner that is accretive to shareholder value.

NRx Corporate Advances
In 2025, our current management team was asked by the board to attempt a revitalization of the Company with a focus on building near-term revenue opportunities . Accordingly, in the twelve months ended September 30, 2025, the Company was able to attract the B Group of Dallas, TX, as a strategic investor and clear the balance sheet of toxic debt in August 2025. This enabled the Company to attract analyst coverage from highly regarded biotechnology analysts and to attract equally regarded health care specialist investors. From an ownership base that was largely retail and debt holder, NRx is now free of convertible debt and approximately 30% owned by institutional investors. As depicted above, the parent company (NRx) was organized into four divisions as depicted above.
NeuroRx, Inc.
NeuroRx, Inc. was the original basis of NRx Pharmaceuticals, focused on development of an innovative drug to treat suicidal bipolar depression (NRX-101). Its CNS focus was interrupted during the Covid years and resumed in 2022. NeuroRx has now expanded to encompass its foundation drug and an injectable sterile products division that has just been granted its first drug approval.
NeuroRx Sterile Products: Aim to Deliver Sterile Injectable Products at Margins Consistent with Innovative Drugs.
A key focus our refocus was to concentrate on immediately revenue-generating drugs, such as preservative-free ketamine, that could rapidly be introduced to the market with minimal regulatory risk. This led the Company to partner with Nephron Pharmaceuticals (West Columbia, SC) and advance blow-fill-seal packaging technology from a compounding pharmacy business model to an FDA-approved drug model using the regulatory expertise on the NRx team.
In the course of developing NRX-101, which was envisioned to be administered following an infusion of Intravenous Ketamine, the Company was directed in 2024 by the FDA to seek a label for use of ketamine in the treatment of depression if there was an intention to use ketamine in conjunction with NRX-101. This request gave rise to what is now a rapidly-emerging commercial opportunity for NRx Pharmaceuticals with its first drug approval received in October 2026. We estimate the current United States demand for sterile injectable ketamine to approximate $400 million and to be expanding at greater than a 15% growth rate as ketamine is increasingly used in hospitals for pain control as well as anesthesia. This estimate does not fully incorporate the potential of ketamine to be used in the treatment of depression and PTSD under our NRX-100 program.
The mission of our NeuroRx Sterile Products division was expanded to encompass the manufacture and immediate commercial distribution of a broader array of sterile injectable products to meet urgent United States market demand. With little public recognition, the injectable sterile products industry in the United States atrophied over the Covid years, in part because of increased costs of pharmaceutical-grade glass and competition for glass-bottle manufacturing lines by new, high-margin innovative biologics. The gap was partially-filled by a rapid growth of compounding pharmacies, attempting to manufacture pharmaceutical products at scale without FDA approval and without full compliance with the Food, Drug, and Cosmetics act. Compounded drugs are manufactured under state pharmacy laws intended for low volume production of drugs that cannot be sourced through the FDA-regulated drug supply chain.
In recent years, FDA has exerted additional enforcement authority, effectively requiring 503b compounders to comply with full Good Manufacturing Practices and issuing enforcement actions against those who do not. 503b compounded goods create major disadvantages for hospital customers because state law limits their expiration date to 90 days or less, which is highly disadvantageous to the pharmacy stocking needs of any hospital. Frequent reports of contaminated sterile compounded products attest to the risk associated with attempting to use compounded sterile drugs as a substitute for properly manufactured, FDA-approved drugs. Moreover, 503b compounded drugs may not be legally sold when an FDA-approved drug is available and not in drug shortage.
Widespread shortages of sterile, injectable drugs are only partially filled by an overseas supply chain. Until now, injectable drugs could not be manufactured in more economical blow-fill-seal packaging because there was no FDA-approved mechanism to transfer the medication from the BFS container to a sterile syringe in the manner that medication could be withdrawn from a glass vial. This challenge was addressed by the luer-lock drug/device combination approved as part of NRx’s Abbreviated New Drug Approval by the US Food and Drug Administration on October 29, 2026 for a preservative-free ketamine product, which has now entered the commercial launch phase. Although the luer-lock was previously incorporated in a water-for-injection product, this was the first drug approval in which this innovation was reviewed by and approved by FDA as a drug/device combination. Extensive regulatory documentation and engineering testing were required in support of this innovation that will provide NRx with a market-leading platform for this and future sterile, injectable products.

The manufacturing innovation, driven by NRx’s collaboration with Nephron Pharmaceuticals (West Columbia, SC) and Rommelag AG (Germany) has led to a cost of goods (COGS) that is a fraction of the former cost of glass vial-packaged drugs. For instance, 900,000 units can be manufactured on a blow fill seal manufacturing line in the same time as 50,000 glass bottles can be filled, stoppered, and packaged. NRx’s prior experience with glass bottling during the Covid years yielded a COGS of about $3.25 per unit, compared with approximately $0.75 per unit with BFS. The cost of buying and managing the glass generally exceeds the cost of the active pharmaceutical ingredient. This high COGS may help explain the diminished supply of sterile injectable products from overseas.
The innovative packaging associated with our first approved product additionally provides benefits to the hospital personnel who must handle the product. When pharmacists, nurses and doctors draw injectable products from traditional glass vials, they must mount a needle on a syringe, pierce a rubber stopper with a needle, and safely dispose of the needle. CDC estimates that hospital-based health care personnel in the United States sustain approximately 385,000 needlestick and other sharps injuries each year, a figure that likely understates the true burden because it excludes non-hospital settings and surveys indicate that 50% or more of injuries go unreported. In addition, the NRx luer vial does not generate “sharps” medical waste, which is costly and complex to dispose of. Staff safety and staff time are at a premium in every U.S. hospital, and customers have applauded the value of the NRx BFS solution. Human factors studies conducted by NRx have demonstrated considerable time savings for medical staff associated with the luer-lock vial compared to traditional glass bottles.
Following the ANDA approval, NRx recruited, trained and certified a seventeen-person sales force, who initiated marketing of the ketamine product with anticipated net margins that are consistent with innovative drugs. This salesforce is comprised of sterile products veterans with decades of customer contact with hospitals, group purchasing organizations, insurers, and federal purchasers.
Efficiencies are driven by the innovative blow-fill-seal (BFS) packaging solution that is far less costly than traditional glass bottle packaging currently used in sterile injectable drugs. NeuroRx continues to develop innovative forms of ketamine to treat depression and PTSD (NRX-100/200) and an oral neuroplastic drug (NRX-101) that has demonstrated phase 2 proof of concept for suicidal bipolar depression and, more recently, for the augmentation of Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression.
NRx Innovative Pharmaceuticals: Developing NMDA Antagonist Drugs to treat Depression and Suicidality
Historically, NeuroRx drug development activities have focused on drugs that enhance neuroplasticity by modulating the N-methyl-D-aspartate (“NMDA”) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings.
NRX-100: Ketamine for treatment of depression and PTSD
Our involvement with ketamine as an innovative drug gave rise to the sterile products division and the near-term revenue described above. Ketamine is widely used to treat depression and suicidality on an off-label basis and the Company has shared extensive clinical trials data to support that use. In 2026 we were awarded Fast Track Designation by the FDA for this indication, the White House issued an executive order guiding the FDA to allow the use of Real World Evidence in support of this indication, and the Congressional Appropriations Committee that regulates the FDA budget guided FDA to allow the use of Real World Evidence for approval of ketamine.
The Company met with the FDA in early 2026 and the Agency agreed to accept Real World Evidence (RWE) in support of Drug Approval. White House and Congressional policy statements were published in support. However, in ongoing correspondence, the Agency asked the Company to demonstrate that the PHQ-9 depression rating scale generally used in RWE is comparable to the Montgomery Asberg Depression Rating Scale (MADRS) typically considered “Fit for Purpose” by the FDA for approval of antidepressants.
To address this regulatory issue, the Company contracted with Osmind, Inc., and Yale University to examine datasets in which SPRAVATO treatment was assessed with both scales. Results demonstrate that the two scales demonstrate nearly identical effect sizes when used to measure reduction of depression in two clinical trials. Based on these findings, the Company will continue its application for Drug Approval.

Based on the Osmind/Yale results (partially depicted above) we believe we have an adequate answer to the FDA’s query regarding PHQ-9 vs. MADRS. Moreover, with the approval of our luer-lock vial, we now have a manufacturing solution for NRX-100 that we believe is compliant with FDA requirements. We expect to initiate submission of the NRX-100 NDA in the remainder of 2026. This submission will be accompanied by a request for Accelerated Approval based on the newly-established Yale/PCORI collaboration (see below).
NRX-101 (D-cycloserine/lurasidone): Our company began with NRX-101 (D-cycloserine+lurasidone) to treat suicidal bipolar depression. NRX-101 was awarded Breakthrough Therapy Designation by the FDA and demonstrated to reduce depression, suicidality, and akathisia in two randomized controlled trials where it demonstrated superiority to lurasidone, a standard of care antidepressant, in relieving symptoms of akathisia and suicidality in both of those trials. Despite the effectiveness of NRX-101 in this indication, the future of twice-daily antidepressant pills as the standard of care for treating depression is rapidly being challenged by interventional psychiatry advances where our Company is actively engaged (see below).
The unexpected, positive development for NRX-101 is the discovery that the ingredients of NRX-101 significantly augment the effectiveness of Transcranial Magnetic Stimulation and potentially enable a rapid (one day) treatment of depression with durable results. Preliminary results in our HOPE Therapeutics Clinics and in the hands of our partners at Harvard McLean Hospital support the results reported by McGirr, Vaughn, Downar, and others (see illustration below). In September 2026, the Defense Advanced Research Projects Agency awarded a Prime Contract to NRx Defense Systems to lead a Phase 2/3 clinical trial that has the potential to support an FDA approval of NRX-101 in conjunction with Rapid, Robotic Transcranial Magnetic Stimulation. The Company is finalizing a Cooperative Research and Development Agreement with the Uniformed Services Health Sciences University to expand this trial to several leading military hospitals.
NRX-200: pH neutral ketamine: As we have gained experience with the use of intravenous ketamine to treat depression through our HOPE Therapeutics division, we have increasingly recognized the ergonomic challenges of administering IV ketamine. IV infusion of ketamine, if done in compliance with laws in most states requires infusion nurses, nurse anesthetists, anesthesiologists, or similar highly-trained personnel. Oral, intramuscular, and intranasal forms of ketamine are believed by many to be less efficacious in treating depression. A steady state of low dose ketamine is optimally-required to achieve the antidepressant effect, which cannot be effected by any of the above routes. An ideal route of administration might be subcutaneous ketamine, which can be delivered via an insulin-type infusion pump with no IV needles or setup.
The barrier to subcutaneous ketamine is that ketamine hydrochloride (HCl), the currently used form of the drug is highly acidic and barred from subcutaneous infusion. Any attempt to raise the pH of ketamine HCl with standard buffers results in its precipitation from solution. NRx has developed and now demonstrated feasibility for a proprietary formulation of ketamine based on an already FDA-approved cyclodextrin vehicle, which has a neutral pH. This form of ketamine NRX-200, is anticipated to be advanced to first-in-human testing in 2027. Should this subcutaneous approach prove successful, we believe that it could become the standard of care for administration of ketamine to treat depression and offer advantages over either intranasal or intravenous administration.
The Sea Change from Traditional Antidepressants to Combined Neuroplastic Care
In the decade since the founding of NeuroRx, treatment of depression has changed considerably. While SSRI/SNRI oral medications remain the most commonly used treatments, NMDA antagonist drugs, psychedelic drugs, and Transcranial Magnetic Stimulation have advanced. To give some perspective on the reported effects of these treatments, the Company presented the illustration below at the 2026 Cantor Fitzgerald Health Care Conference. All results shown are from published, peer-reviewed papers, although these results are not recognized by the FDA as labeling claims for any product.
While we are far from a standard of care treatment that will replace traditional oral antidepressants, it may be important to recognize that the efficacy claims identified in the most successful clinical trials of psychedelic medications do not exceed the efficacy seen with traditional antidepressants, although the psychedelic drugs are generally administered on one or several occasions, rather than several times a day. Intravenous Ketamine effectiveness has been reported in multiple clinical trials to exceed that of oral antidepressants, although the question of whether IV ketamine can be used as a chronic treatment remains open.
These reported data underlie the enthusiasm for exploring a one day or multiday treatment with focused Transcranial Magnetic Stimulation, particularly among military personnel and first responders for whom traditional oral antidepressants and newer psychedelic medications are often incompatible with continued military service. This recognition underlies the STRENGTHEN program of the Defense Advanced Research Projects Agency (DARPA) and provides the basis for the SPARC-TMS clinical trial (see below).

Figure 1: Comparison of reported effectiveness observed for traditional antidepressants, recent psychedelic clinical trials, intranasal and intravenous ketamine, and Transcranial Magnetic Stimulation, with and without addition of D-cycloserine. The data above, while published in peer-reviewed studies are not a direct statistical comparison and none of these data have resulted in efficacy claims granted by the Food and Drug Administration.
NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (“HOPE”), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (“TMS”), digital therapeutics, and hyperbaric therapy. HOPE Therapeutics was founded by the Company in February 2024, with the intent of developing a medical care delivery organization focused on providing cutting-edge, comprehensive interventional psychiatric treatment with the most effective treatments available, including NMDA-targeted and other neuroplastic drugs, such as ketamine, Spravato and NRX-101, neuromodulatory devices, such as TMS, hyperbaric therapy, digital therapeutics, and medication management. During 2025, the Company developed the operating model for HOPE and made initial clinic acquisitions with funding from the B-Group. HOPE generated its first clinical revenue in the fourth quarter of 2025 and as of September 30, 2026, operates in six locations in Florida, including Dura Medical, Cohen Associates, and three clinics founded by HOPE. The enterprise offers precision-based interventional psychiatry services, including ketamine infusion therapy, TMS, Spravato®, stellate ganglion blocks, and psychotherapy. HOPE is supported by HTX Management Company, LLC (“HTX”), a majority owned subsidiary of HOPE organized as a Delaware limited liability company, for the purpose of supporting future back-end operations associated with the growing network of HOPE clinics.
HOPE Therapeutics: Transforming the Delivery of Interventional Psychiatry
In its first year of operation, HOPE’s leadership recognized the widespread challenges affecting the TMS clinic industry and chose to partner in the development of innovative technologies with thought leaders at Harvard McLean hospital and the Yale Department of Psychiatry. Accordingly, HOPE deferred its plans for widespread expansion via debt-based acquisition and focused on establishing a footprint in Florida that would advance new technologies to benefit patients, focusing on Robotic Neuronavigated Transcranial Magnetic Stimulation.
This led to HOPE’s partnerships with Neurocare, AG, a German manufacturer of TMS equipment and Zeta Surgical, Inc., manufacturer of the first neuronavigated, robotic precision TMS system. This partnership led to the HOPE’s selection by DARPA to lead the SPARC-TMS trial. When combined with NRx’s NRX-101 oral medication, the Company aims to deliver precision and efficacy in treating depression and PTSD that surpasses currently available solutions.
NRx Defense Systems
During 2026, NRx founded NRx Defense Systems, Inc. (“NRXD”) as a qualified military contractor in response to an invitation from the Defense Advanced Research Projects Agency (DARPA) to submit a bid under their Broad Area Announcement. NRXD focuses on military and first-responder uses of NRx/HOPE technology in partnership with DARPA, the Uniformed Services Health Sciences University (USU), the Walter Reed National Military Medical Center/Henry Jackson Foundation, and first responder organizations. In October 2026, NRXD was awarded the $11.25 million Prime Contract to lead the SPARC-TMS clinical trial (07227103) by the Defense Advanced Research Projects Agency (DARPA) as a lead component of the STRENGTHEN program focused on treating depression, PTSD, and suicidality in the military. NRXD is partnered with Harvard McLean Hospital and Arizona State University in the conduct of this trial.
NRx Defense Systems is now a fully-qualified DARPA contractor that meets the security and cybersecurity requirements of current and future defense contracts. NRXD has been advised by DARPA that it has satisfied its initial milestones and its first two invoices are approved for payment in Q4 2026. NRXD is anticipated to be funded through non-dilutive capital.
GeNeuro, Inc.
Background on Geneuro and Human Endogenous Retroviruses
Retroviruses were first discovered in 2005, with the discovery of the HTLV3 virus that causes AIDS. This class of viruses infects a person by blood contact, enters the person’s genome, and replicates to form viral particles that may infect others. Although HTLV3 is widely known because of its role in AIDS, Human Endogenous Retroviruses (HERVs) are largely unknown outside the field of molecular biology. Yet, emerging data suggests that HERVs may play a causative role in major neurodegenerative diseases including ALS, Multiple Sclerosis, Schizophrenia, Fronto Temporal Dementia, and other devastating conditions whose cause was previously unknown. HERVs are believed to be “fossils” of ancient viruses that infected primates 100,000 or more years ago and whose proteins were essential for development of the human brain and the human placenta. While an active retrovirus, such as HTLV3 may be controlled with anti-retroviral drugs, the damage caused by HERV proteins is not a true viral infection and the specific toxic proteins must be targeted to attenuate human disease. An analogy is the well understood cause of macular degeneration of the eye by Vascular Edothelial Growth Factor (VEGF). Although no drug has been shown to prevent replication of VEGF, drugs that neutralize VEGF once expressed in the eye are shown to prevent blindness in macular degeneration. Similarly, the drugs under development by Geneuro are known to neutralize the toxic envelope proteins of HERV K and HERV W.

Figure 2: HTLV3, a modern retrovirus, compared to Human Endogenous Retroviruses
The illustration below from the Company’s presentation at the Cantor Fitzgerald Health Care Conference illustrates the challenges to humanity posed by HERVs and the potential to cure previously mysterious devastating diseases.

GeNeuro, Inc. owns or co-owns 7 patent families with more than 150 patents granted or in prosecution.
Recent evidence demonstrates that when elements of HERVs aberrantly enter the “reading frame” and begin replicating in adult life, they may cause devastating neurodegenerative diseases. GeNeuro is developing GNK-301 for the treatment of ALS through its partnership with the U.S. National Institutes of Health (“NIH”) through a Cooperative Research and Development Agreement (CRADA) and shared patents and has been selected in the first round of the 2026 Congressionally Directed Medical Research Program (“CDMRP”). GeNeuro, Inc. is additionally partnered through shared patents related to treatment of Schizophrenia with the Fondation FondaMental of France. GeNeuro owns patented monoclonal antibodies developed with more than EU 180 million of European investment funding to treat Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), psychosis, and Type I diabetes (“T1D”) that may be caused by Human Endogenous Retroviruses (“HERVs”).
The formation of GeNeuro, though not its background, has previously been described briefly in the Company’s filings. In 2022, NRx’s founder Jonathan Javitt began a scientific collaboration with Prof. Marion Leboyer, MD, PhD, the Chair of Psychiatry at INSERM, a French University and the CEO of France’s Fondation FondaMental. Prof. LeBover provided insight on a novel mechanism underlying schizophrenia, specifically the finding that 50% of patients entering French hospitals with psychosis demonstrate abnormal blood levels of a neurotoxic protein linked to Human Endogenous Retrovirus W, which serves as the viral envelope protein. This abnormal protein is found in only 2% of normal blood donors and is now known to disrupt the NMDA receptor, a molecular target with which NRx has considerable expertise. A monoclonal antibody to HERV W Envelope protein had been manufactured by GeNeuro, SA, headquartered in Geneva and advanced to the clinic for multiple sclerosis, long Covid, and Type I diabetes, but not for schizophrenia. A second monoclonal antibody, targeting the HERV K Envelope protein had been developed to treat ALS in partnership with the US National Institutes of Health.
Key Third Quarter Results
In the third quarter of 2026 and through the date of this Report, the Company achieved several operational, regulatory and financing milestones, including the following:
NeuroRx Pharmaceuticals: Sterile, Injectable Generic Products
| ● |
On October 29, 2026, the FDA approved the Company’s Abbreviated New Drug Application, or ANDA, for preservative-free ketamine and gave the Company clearance to market the product with an initial two year labeled expiration date, which the Company aims to extend over the next year. The Company is the first supplier to obtain FDA approval of a Blow-Fill-Seal (BFS) manufactured presentation of ketamine. Unlike traditional glass bottling of sterile products, which incurred a unit cost of $3.50 per dose during the Company’s prior experience during Covid, NRx has now demonstrated its capacity to manufacture at considerably lower cost with margins that rival those of innovative, rather than generic drugs, which typically exceed 80%. Ketamine, and similar sterile injectable products are frequently in drug shortage in the US. Management believes that the high cost of manufacture in glass bottles compared to the relatively low prices paid by hospitals have contributed to that shortage. |
| ● |
In November 2026, we trained and certified a veteran 17 person sales force with existing coverage of more than 80% of the current $400 million US market for generic ketamine. Presales of the product have now been initiated with anticipated full scale units shipped in early January 2027. The salesforce has decades of experience in the sale of sterile injectable products to the hospital market. The Company anticipates net operating margins from sales of its ketamine product comparable to that of many innovative drug products. |
| ● |
Notably, despite the absence of preservatives in the NRx product, no degradation of the ketamine active ingredient has been seen at any time point. The Company also completed three commercial-scale process validation lots in compliance with applicable good manufacturing practices and demonstrated its ability to manufacture at scale of approximately 550,000 units per manufacturing cycle. This affords the Company the potential to supply approximately 55 million units per year on its first FDA-qualified manufacturing line. The Company is in the process of qualifying a second FDA-approved manufacturing line of equal capacity. |
| ● |
In September 2026 the Company contracted with Rommelag AG, a leading German supplier of Blow-Fill-Seal sterile manufacturing equipment to deliver an additional manufacturing line to West Columbia, South Carolina for the Company’s use. This additional capacity will afford the Company the ability to manufacture in additional vial sizes and to add additional products. |
| ● |
In September 2025, the Company submitted a Citizen Petition to the Secretary of Health and Human Services seeking to have the Benzethonium Chloride preservative removed from all marketed forms of ketamine. Ketamine is one of only two marketed drugs in the US that continues to use this preservative with known toxicity. As NRx continues to demonstrate an ability to supply sufficient ketamine to avoid any possibility of a drug shortage, the Company will continue to pursue the Citizen Petition. |
NeuroRx Pharmaceuticals: Innovative Products
| ● |
The application for approval of NRX-100 was additionally affected by FDA’s decision to examine the medical device aspects of the luer-lock connection that is incorporated in the NRX-100 drug vial. This matter was resolved in August 2026. |
| ● |
NRX-101: An NDA filing for NRX-101 for its original indication of treating suicidal bipolar depression has been initiated with the submission of the Module 3 manufacturing file to the FDA. NRX-101 was previously granted Breakthrough Therapy Designation by the FDA, and the Company is requesting rolling review of the NDA. Breakthrough Therapy Designation is intended to facilitate the development and expedite the review of drugs intended to treat serious conditions where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. Based on the clinical data generated to date, the Company intends to seek FDA approval of NRX-101 for the treatment of patients with bipolar depression and suicidal ideation. The Company has now partnered with the Bipolar Action Network, led by Prof. Andrew Nirenberg of Harvard Mass General to conduct a confirmatory clinical trial. |
| ● |
However, based on rapidly emerging data that demonstrate an enhancement of Transcranial Magnetic Stimulation by D-cyclosrine, DARPA has awarded the Company a contract to support a Phase 3 trial in this indication. On September 29, 2026, NRXD entered into a prime contract with DARPA to conduct the SPARC-TMS trial. The contract has an aggregate value of approximately $11.2 million, of which approximately $6.7 million has been obligated; additional funding is subject to appropriations and DARPA's exercise of funding options. Payments are made upon DARPA's acceptance of specified milestones, and either party may terminate the contract under certain circumstances, including if the program is determined unlikely to achieve its objectives. |
| ● |
Based on these advances that emerged over the past year, the Company is advancing development of NRX-101 for use in combination with transcranial magnetic stimulation, or TMS. The FDA has authorized the Company to proceed with the SPARC-TMS clinical trial, a Phase 2b/3 study evaluating NRX-101 in combination with robotically controlled TMS in patients with treatment-resistant depression. In June 2026, the FDA also authorized an Intermediate Population Expanded Access Protocol for use of NRX-101 in combination with accelerated TMS for eligible patients who are unable to participate in the clinical trial. This contract is now in place and initial milestones have been met with an accepted invoice for approximately $2.2 million. |
| ● |
Based on the DARPA support, we are additionally establishing a Cooperative Research and Development with the Uniformed Services Health Sciences University (USU) that will enable extension of the SPARC-TMS protocol to military treatment facilities including Walter Reed National Military Medical Center. |
| ● |
The Company anticipates that success in the SPARC-TMS trial would be consistent with the filing of a New Drug Application for the use of NRX-101 to augment the effects of TMS, potentially providing the Company with a path to approval based on the provision of non-dilutive capital by the U.S. Department of War. |
HOPE Therapeutics Advances
| ● |
HOPE has partnered with Neurocare AG (Munich) and Zeta Surgical (Boston) to develop the first robotic, neuro-navigated system for Transcranial Magnetic Stimulation. This has the potential to deliver a one day treatment for depression with substantial durability, particularly when combined with NRX-101. This treatment consists of robotic neuronavigation, or Rapid Robotic Transcranial Magnetic Stimulation (RRTMS) where an MRI scan is used to identify the areas of lost connectivity in the brain that may drive depression and proprietary software is used to focus the TMS coil on those treatment targets. HOPE Therapeutics treated the world’s first RRTMS patients in Q3 in our Sarasota, FL location. Meaningful clinical improvement was seen, although formal measurement of improvement was deferred until the SPARC-TMS trial. |
| ● |
During the third quarter of 2026, all HOPE clinic staff were trained in Good Clinical Practices in preparation for their participation in SPARC-TMS. |
NRx Defense Systems Advances
| ● |
On September 29, 2026, NRx Defense Systems, Inc. (“NRXD”), a subsidiary of the Company, entered into a prime contract with the Defense Advanced Research Projects Agency, or DARPA, to conduct the Synaptic Plasticity Augmented Rapid Circuit Stimulation, or SPARC-TMS clinical trial evaluating NRX-101 in combination with robotically controlled transcranial magnetic stimulation for treatment-resistant depression. The contract has an aggregate value of approximately $11.2 million, of which approximately $6.7 million was initially obligated by DARPA, with additional funding subject to the availability of appropriations and DARPA’s exercise of funding options. The contract has an 18-month performance period. The SPARC-TMS protocol has received FDA and Institutional Review Board approval. The Company is currently collaborating with other branches of the US military including the Uniformed Services Health Sciences University (USU) to broaden the collaboration to include several military treatment facilities. |
| ● |
Depression, PTSD, and suicidality are 4x more prevalent in military personnel and first responders. Treatment of depression has become a “Force Readiness” issue for the Department of War and therefore a research priority for DARPA. As stated in the Prime Contract for the SPARC-TMS trial, use of traditional antidepressants (SSRI/SNRI) is not compatible with active service in the military. Similarly psychedelic drugs are unlikely to be compatible with active duty. Accordingly, the RRTMS protocol being developed under the NRXD prime contract has potential to become the standard of care for military personnel, first responders, and others. |
| ● |
In the process of qualifying NRXD to serve as Prime Contractor for the SPARC-TMS project, the Company established security and cybersecurity clearances that qualify NRXD to participate in additional health-related Defense projects. Management expects NRXD to provide a net contribution margin to NRx Pharmaceuticals on a forward-looking basis. |
GeNeuro Advances
| ● |
In June 2026, GeNeuro, Inc., a newly-formed Florida entity was awarded all assets of the former GeNeuro SA, by the Swiss liquidator, including all preclinical and clinical data, master cell lines, and more than 150 patents related to the use of anti-Human Endogenous Retrovirus antibodies to treat Central Nervous System diseases, including ALS, Multiple Sclerosis, and Schizophrenia. GeNeuro retained scientists previously employed by GeNeuro SA and reinstituted the collaborations with the Fondation FondaMental and the NIH. A month later, GeNeuro, Inc. passed the first selection round for the Congressional Directed Medical Research Program administered by the Department of War for potential funding of a clinical trial to treat ALS. GeNeuro is similarly in consideration by the Government of France to advance its work in Schizophrenia and has been qualified for funding by the Canton Government of Basel, Switzerland for resources to continue the work in MS and other neurodegenerative diseases. |
| ● |
In August 2026 GeNeuro, Inc., initiated GMP manufacturing of GNK-301, its antibody against the HERV K Envelope protein and currently anticipates initiating Phase 1 clinical trials in patients with ALS in the United States and Europe in the second half of 2027. GeNeuro and the U.S. National Institute of Neurological Disorders and Stroke were also selected in the first round of the Congressionally Directed Medical Research Programs process for potential funding relating to therapeutic and biomarker development in ALS. |
| ● |
GeNeuro similarly initiated GMP manufacture of Temelimab, its antibody against HERV W Envelope protein, which has demonstrated decreased neurodegeneration compared to placebo in a placebo-controlled trial in Relapsing, Remitting Multiple Sclerosis. HERV W Envelope protein has been detected in approximately 50% of patients presenting to European psychiatric hospitals with acute schizophrenia and is now known to disrupt the brain’s NMDA receptor. NMDA blockade, first described by NRx’s cofounder Daniel Javitt, PhD, MD in 1987 is well-known to cause psychosis and is the mechanism that underlies phencyclidine (angel dust) – induced psychosis and anti-NMDA antibody-induced psychosis. GeNeuro has patented this mechanism of action together with the Fondation FondaMental of Paris and anticipates initiating a Phase 2/3 trial of Temelimab in the treatment of psychosis with European support in late 2027. |
Overview of GeNeuro-based Activities
Human Endogenous Retroviruses (“HERVs”) and their potential role in the pathogensis of CNS disease began to be appreciated around 2010 and the science is not widely known. The majority of the HERV literature related to ALS has emanated from the US National Institutes of Health, while the literature related to Multiple Sclerosis and Schizophrenia has emanated from ItemEurope and the United Kingdom. NRx’s involvement in this area began with its collaboration with the Fondation FondaMental and its CEO, Prof. Marion Leboyer, who serves as a member of the NRx advisory board. Prof. Leboyer together with Dr. Herve Perron first recognized the potential role of Human Endogenous Retrovirus (HERV-W) in causing schizophrenia and the potential role of an anti HERV-W envelope protein antibody as a disease-modifying drug to treat schizophrenia and other forms of psychosis. (U.S. patent application 2024/0301040 A1). The antibody was developed by a French biotechnology company owned by GeNeuro, SA, which was involved in a liquidation following a failed Covid-related clinical trial. The schizophrenia patent is jointly owned with Fondation FondaMental.
In parallel with the above work, the Company established a Cooperative Research and Development Agreement with the National Institute for Neurologic Diseases and Stroke (NINDS) of the US National Institutes of Health (NIH) to explore the role of HERV K Envelope Protein in the pathogenesis of ALS and the potential role of anti-HERV K antibody in treating ALS. The patent related to ALS (U.S. 10,723,787 B2) was co-invented with the US National Institutes of Health and shared under an intellectual property agreement. Dr. Herve Perron, formerly Chief Scientist of GeNeuro has joined the Company’s initiative as its Chief Scientific Advisor.
In May 2026, the Company was advised by Swiss authorities that NRx was the winning bidder in a liquidation sale of the GeNeuro assets. These assets include a broad patent portfolio and related cell lines, antibodies, regulatory files, and data from three completed human clinical trials. The GeNeuro portfolio offers potential treatments for Amyelotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Schizophrenia, Autism, Optic Neuritis, and Type I Diabetes. The acquisition of the GeNeuro assets was finalized during Q2 of 2026 and the Company anticipates supporting GeNeuro through investment channels that are not dilutive to core NRx investors. GeNeuro has already won two first-round selections for the 2026 Congressionally Directed Medical Research Program (CDMRP) and has been invited to submit final proposals.
GeNeuro, Inc. has now initiated manufacturing of human-grade GNK-301 (anti-HERV-K envelope protein antibody) for a planned First in Human trial in patients with ALS targeted to commence in July 2027.
Financing
In May 2025, the Company reinstated the at-the-market offering and increased the maximum aggregate offering amount and filed a prospectus supplement under the offering agreement for an aggregate of $20,000,000. During the year ended December 31, 2025, the Company sold an aggregate of 2,277,177 shares of common stock for approximately $6.54 million, net of $0.2 million in offering costs. During the three and nine months ended September 30, 2025, the aggregate net cash proceeds to the Company from the at-the-market offering were approximately $3.7 million and $4.8 million. During the three and nine months ended September 30, 2026, the aggregate net cash proceeds to the Company from the at-the-market offering were approximately $0 and $11.8 million, respectively.
On June 4, 2026, the Company completed an underwritten public offering of 6,378,942 shares of its common stock at a public offering price of $3.50 per share, which included the exercise of the underwriters’ over-allotment option. The Company received net proceeds of approximately $20.7 million after deducting underwriting discounts, commissions, and other offering expenses.
Pursuant to the Anson Purchase Agreement, on January 28, 2025, the Company issued $5.4 million of Third Tranche Anson Notes at an 8% original issue discount for total cash proceeds of approximately $5.0 million. On August 18, 2025, the Company entered into the Second RD Purchase Agreement with certain accredited investors for the sale of an aggregate of 3,959,999 shares of common stock, at a purchase price of $1.65 per share. The Second Registered Direct Offering closed on August 18, 2025, and resulted in net proceeds of approximately $6.2 million, after deducting placement agent fees and other offering-related expenses of approximately $0.3 million. On September 30, 2025, the 1,870,960 shares underlying Anson Warrants were exercised for cash proceeds of $3.09 million.
Activities of NRXD to date have been funded by government contracts.
Activities of GeNeuro, Inc., are anticipated to be funded by a combination of public and private capital.
Although no assurances can be given, management believes that it will be able to secure necessary financing to support and execute its business plan and achieve its projected revenue objectives.
Since inception, the Company has incurred significant operating losses. For the three months ended September 30, 2026 and 2025, the Company’s net loss was $2.2 million and $5.9 million, respectively. For the nine months ended September 30, 2026 and 2025, the Company’s net loss was $20.1 million and $29.00 million, respectively. As of September 30, 2026, the Company had an accumulated deficit of $327.0 million, a stockholders’ deficit of $2.0 million and a working capital deficit of $7.0 million.
Going Concern
Although the Company is entering its first quarter of commercial drug sales, the Company’s ongoing clinical activities have heretofore generated losses from operations. Some losses were associated with delays in obtaining insurance billing authorization for newly established HOPE clinics, a condition that has now been rectified. Should future activities continue to generate losses and net cash outflows from operations. The Company plans to pursue additional equity or debt financing or refinancing opportunities to fund ongoing clinical activities, and for the general corporate purposes of the Company. Such arrangements may take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures, or other agreements. The sale of equity could result in additional dilution to the Company’s existing stockholders. The Company cannot make any assurances that revenues from commercial drug sales and from clinical services provided by HOPE Therapeutics will be sufficient to fund operations or that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company’s business and operations and could also lead to a reduction in the Company’s operations. The Company will continue to carefully monitor the impact of its continuing operations on its working capital needs and debt repayment obligations. As such, the Company has concluded that until the volume of commercial sales and its growth trajectory can be established, doubt exists about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements. The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one of the Company’s product candidates.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern.
Additionally, amounts associated with the DARPA contract were not recognized during the reporting period because the applicable contractual milestones were not achieved until the subsequent reporting period. Consequently, the operating loss reported for the period does not reflect the financial impact associated with the subsequent achievement of these milestones.
Components of Results of Operations
Revenue
The Company recognizes patient service revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized as performance obligations are satisfied, which occurs over time as patients simultaneously receive and consume the benefits of the services provided. Each treatment or visit generally represents a separate contract.
Procedural services, such as ketamine infusions, esketamine administration, TMS sessions, and SGB/epidural procedures, are recognized at the point in time when services are rendered.
For the three and nine months ended September 30, 2026, the Company recorded total revenue of approximately $1.2 million and $3.3 million, respectively, which mostly was attributable to patient services provided by Dura following its acquisition on September 8, 2025. Prior to the acquisition, the Company did not generate revenue as it was in the development stage and primarily focused on corporate formation, financing, and acquisition-related activities.
The initial post-acquisition revenue reflects only a partial period of operations and therefore is not indicative of the Company’s expected ongoing revenue levels. Management anticipates that revenue will increase in subsequent periods as Dura’s operations are fully integrated and additional clinical capacity, patient volume, insurance reimbursement and service lines are expanded under the Company’s ownership.
Operating Expenses
Cost of patient services
Cost of patient services consists primarily of direct expenses associated with providing healthcare services, including salaries and benefits for clinical personnel, medical supplies, pharmaceuticals, and other costs directly attributable to patient care. These costs are expensed as incurred.
For the three and nine months ended September 30, 2026, cost of patient services related solely to operations of Dura following the Company’s acquisition on September 8, 2025. Given the limited period of post-acquisition operations, current cost levels are not representative of the Company’s expected ongoing operating costs. Management anticipates that cost of patient services will increase in proportion with the expected growth in patient volumes and expansion of clinical activities in future periods.
Research and development expense
The Company’s research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and equity-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.
Selling, general and administrative expense
Selling, general and administrative expenses consist primarily of salaries, stock-based compensation, consultant fees, and professional fees for legal and accounting services.
Settlement (income) expense
Settlement (income) expense during the three and nine months ended September 30, 2026, consists of amounts related to the resolution of legal claims and income recognized from the reduction of previously accrued settlement liabilities, as certain matters were settled for less than originally estimated.
Results of operations for the three months ended September 30, 2026 and 2025
The following table sets forth the Company’s selected statements of operations data for the following periods (in thousands):
| September 30, |
Change in |
|||||||||||
| 2026 |
2025 |
Dollars |
||||||||||
| Net patient service revenue |
$ | 1,159 | $ | 242 | $ | 917 | ||||||
| Operating expense: |
||||||||||||
| Cost of patient services |
874 | 97 | 777 | |||||||||
| Research and development |
1,808 | 1,429 | 379 | |||||||||
| Selling, general and administrative |
6,560 | 2,808 | 3,752 | |||||||||
| Depreciation and amortization |
62 | 26 | 36 | |||||||||
| Settlement expense |
— | (94 | ) | 94 | ||||||||
| Total operating expense |
9,304 | 4,266 | 5,038 | |||||||||
| Loss from operations |
(8,145 | ) | (4,024 | ) | (4,121 | ) | ||||||
| Other expense (income): |
||||||||||||
| Interest income |
(4 | ) | (2 | ) | (2 | ) | ||||||
| Interest expense |
239 | — | 239 | |||||||||
| Change in fair value of convertible note payable |
— | 1,502 | (1,502 | ) | ||||||||
| Change in fair value of warrant liabilities |
(6,204 | ) | 4,963 | (11,167 | ) | |||||||
| Loss on convertible note conversions |
— | 772 | (772 | ) | ||||||||
| Gain on exercise of warrants |
— | (5,369 | ) | 5,369 | ||||||||
| Income from equity method investments |
(1 | ) | — | (1 | ) | |||||||
| Total other expense |
(5,970 | ) | 1,866 | (7,836 | ) | |||||||
| Net loss |
$ | (2,175 | ) | $ | (5,890 | ) | $ | 3,715 | ||||
Net patient service revenue
For the three months ended September 30, 2026 and 2025, the Company recorded $1.2 million and $0.2 million, respectively, in net patient service revenues from the clinical services provided by Dura following the acquisition on September 8, 2025.
Operating expense
Cost of patient services
For the three months ended September 30, 2026, the Company recorded $0.9 million in costs of patient services, as compared to $0.1 million incurred during the three months ended September 30, 2025. This increase is attributed to the acquisition of Dura on September 8, 2025.
Research and development expense
For the three months ended September 30, 2026, the Company recorded $1.8 million of research and development expense, as compared to approximately $1.4 million for the three months ended September 30, 2025. The increase of $0.4 million is primarily related to a $0.3 million increase in research and development salaries and $0.4 million increase in clinical trials and development, partially offset by a decrease of $0.3 million of contractor costs. The research and development expense for each of the three months ended September 30, 2026 and 2025, includes less than $0.1 million of non-cash stock-based compensation.
Selling, general and administrative expense
For the three months ended September 30, 2026, the Company recorded $6.6 million of selling, general and administrative expense, as compared to approximately $2.8 million for the three months ended September 30, 2025. The increase of $3.7 million is related primarily to an increase of $1.3 million in employee costs, $0.5 million in contractor costs, $0.4 million in legal fees, and $0.7 million in marketing costs. Selling, general and administrative expense includes $0.2 million and less than $0.1 million of non-cash stock-based compensation for the three months ended September 30, 2026 and 2025, respectively.
Settlement expense (income)
For the three months ended September 30, 2026, the Company recognized a settlement loss of $0. The Company recorded $0.1 million in settlement gains during the three months ended September 30, 2025. These gains consisted of amounts related to the resolution of legal claims and income recognized from the reduction of previously accrued settlement liabilities, as certain matters were settled for less than originally estimated.
Depreciation and amortization
Depreciation and amortization expense increased to $62 thousand for the three months ended September 30, 2026, compared to $26 thousand for the same period in 2025, primarily due to the recognition of depreciation and amortization on property and equipment and intangible assets acquired in the Dura acquisition completed in September 2025.
Other expense (income)
Interest income
For the three months ended September 30, 2026, the Company recorded less than $0.1 million of interest income, as compared to less than $0.1 million of interest income for the three months ended September 30, 2025.
Interest expense
For the three months ended September 30, 2026, the Company recorded $0.2 million of interest expense related to accrued interest on the refund liability arising from the termination of the License Agreement with Alvogen. For the three months ended September 30, 2025, the Company recorded $0 of interest expense.
Change in fair value of convertible notes payable
For three months ended September 30, 2026, the Company recorded a loss of $0 related to the change in fair value of the convertible notes payable which are accounted for under the fair value option. For the three months ended September 30, 2025, the Company recorded a loss of $1.5 million related to the change in fair value of the convertible note payable which is accounted for under the fair value option.
Change in fair value of warrant liabilities
For the three months ended September 30, 2026, the Company recorded a gain of $6.2 million related to the change in fair value of the warrant liabilities, as compared to a loss of $5.0 million for the three months ended September 30, 2025. The gain recognized during the 2026 period was primarily attributable to changes in the Company’s common stock price, which impacted the fair value of the outstanding warrant liabilities.
Loss on convertible note conversions
For the three months ended September 30, 2026, the Company recorded a loss of $0 related to convertible note conversion, as compared to a loss of $0.8 million during the three months ended September 30, 2025. These conversions were calculated as the difference between the conversion price per the terms of the Anson first tranche senior secured convertible notes agreements relative to the fair value of the common stock on the date of conversion as described further under Note 9 in the accompanying unaudited condensed consolidated financial statements.
Gain on exercise of warrants
For the three months ended September 30, 2026 and 2025, the Company recorded $0 and $5.4 million gain on the exercise of Anson warrants, resulting from the settlement of warrant liabilities for exercised warrants, respectively (See Note 11 in the accompanying unaudited condensed consolidated financial statements).
Income from equity investments
For the three months ended September 30, 2026, the Company recorded a gain of less than $0.1 million related to its investment in Cohen & Associates LLC, which is recorded at cost and adjusted for the Company’s proportionate share of Cohen & Associates’ net income or loss. Please see Note 18 in the accompanying unaudited condensed consolidated financial statements for further information on the investment in Cohen & Associates.
Results of operations for the nine months ended September 30, 2026 and 2025
The following table sets forth the Company’s selected statements of operations data for the following periods (in thousands):
| September 30, |
Change in |
|||||||||||
| 2026 |
2025 |
Dollars |
||||||||||
| Net patient service revenue |
$ | 3,328 | $ | 242 | $ | 3,086 | ||||||
| Operating expense: |
||||||||||||
| Cost of patient services |
2,180 | 97 | 2,083 | |||||||||
| Research and development |
5,233 | 3,219 | 2,014 | |||||||||
| Selling, general and administrative |
15,118 | 8,492 | 6,626 | |||||||||
| Depreciation and amortization |
196 | 28 | 168 | |||||||||
| Settlement (income) expense |
(3 | ) | 6 | (9 | ) | |||||||
| Total operating expense |
22,724 | 11,842 | 10,882 | |||||||||
| Loss from operations |
(19,396 | ) | (11,600 | ) | (7,796 | ) | ||||||
| Other expense (income): |
||||||||||||
| Interest income |
(15 | ) | (8 | ) | (7 | ) | ||||||
| Interest expense |
708 | — | 708 | |||||||||
| Change in fair value of convertible note payable |
— | 8,032 | (8,032 | ) | ||||||||
| Change in fair value of warrant liabilities |
42 | 8,481 | (8,439 | ) | ||||||||
| Loss on issuance of Registered Direct Offering |
— | 730 | (730 | ) | ||||||||
| Loss on Consideration Shares and Warrants |
— | 1,277 | (1,277 | ) | ||||||||
| Loss on convertible note conversions |
— | 4,239 | (4,239 | ) | ||||||||
| Gain on exercise of warrants |
— | (5,369 | ) | 5,369 | ||||||||
| Income from equity method investments |
(6 | ) | — | (6 | ) | |||||||
| Total other expense |
729 | 17,382 | (16,653 | ) | ||||||||
| Loss before tax |
(20,125 | ) | (28,982 | ) | 8,857 | |||||||
| Net loss |
$ | (20,125 | ) | $ | (28,982 | ) | $ | 8,857 | ||||
Net patient service revenue
For the nine months ended September 30, 2026 and 2025, the Company recorded $3.3 million and $0.2 million in net patient service revenues from the clinical services provided by Dura following the acquisition on September 8, 2025.
Operating expense
Cost of patient services
For the nine months ended September 30, 2026, the Company recorded $2.2 million in costs of patient services, as compared to $0.1 million incurred during the nine months ended September 30, 2025. This increase can be attributed to the acquisition of Dura on September 8, 2025.
Research and development expense
For the nine months ended September 30, 2026, the Company recorded $5.2 million of research and development expense, as compared to approximately $3.2 million for the nine months ended September 30, 2025. The increase of $2.0 million is primarily related to a $1.3 million increase in clinical trials and development, a $0.9 million increase in patent expenses, and a $0.4 million increase in research & development salaries, partially offset by a $0.7 million decrease in contractor costs. The research and development expense for each of the nine months ended September 30, 2026 and 2025, includes less than $0.1 million of non-cash stock-based compensation.
Selling, general and administrative expense
For the nine months ended September 30, 2026, the Company recorded $15.1 million of selling, general and administrative expense, as compared to approximately $8.5 million for the nine months ended September 30, 2025. The increase of $6.6 million is related primarily to an increase of $2.3 million in employee costs, $1.4 million in contractor costs, and $1.1 million in marketing costs. Selling, general and administrative expense includes $0.4 million and $0.1 million of non-cash stock-based compensation for the nine months ended September 30, 2026 and 2025, respectively.
Settlement expense (income)
For the nine months ended September 30, 2026, the Company recognized a settlement income of less than $0.1 million resulting from certain legal matters that were settled in 2026. The Company recorded less than $0.1 million in settlement losses during the nine months ended September 30, 2025.
Depreciation and amortization
Depreciation and amortization expense increased to $0.2 million for the nine months ended September 30, 2026, compared to less than $0.1 million for the same period in 2025, primarily due to the recognition of depreciation and amortization on property and equipment and intangible assets acquired in the Dura acquisition completed in September 2025.
Other expense (income)
Interest income
For the nine months ended September 30, 2026, the Company recorded less than $0.1 million of interest income, as compared to less than $0.1 million of interest income for the nine months ended September 30, 2025.
Interest expense
For the nine months ended September 30, 2026, the Company recorded $0.7 million of interest expense related to accrued interest on the refund liability arising from the termination of the License Agreement with Alvogen. For the nine months ended September 30, 2025, the Company recorded $0 of interest expense.
Change in fair value of convertible notes payable
For nine months ended September 30, 2026, the Company recorded a loss of $0 related to the change in fair value of the convertible notes payable which are accounted for under the fair value option. For the nine months ended September 30, 2025, the Company recorded a loss of $8.0 million related to the change in fair value of the convertible note payable which is accounted for under the fair value option.
Change in fair value of warrant liabilities
For the nine months ended September 30, 2026, the Company recorded a loss of less than $0.1 million related to the change in fair value of the warrant liabilities, as compared to a loss of $8.5 million for the nine months ended September 30, 2025. The decrease in loss during the nine months ended September 30, 2026 is attributable to the warrants issued in conjunction with the First, Second and Third Tranches of the Anson Notes, additional shares of Anson Warrants issued as a result anti-dilutive provision, as well as increase in the Company’s stock prices.
Loss on convertible note conversions
For the nine months ended September 30, 2026, the Company recorded a loss of $0 related to convertible note conversion, as compared to a loss of $4.2 million during the nine months ended September 30, 2025. These conversions were calculated as the difference between the conversion price per the terms of the Anson first tranche senior secured convertible notes agreements relative to the fair value of the common stock on the date of conversion as described further under Note 9 in the accompanying unaudited condensed consolidated financial statements.
Gain on exercise of warrants
For the nine months ended September 30, 2026 and 2025, the Company recorded $0 and $5.4 million gain on the exercise of Anson warrants, resulting from the settlement of warrant liabilities for exercised warrants, respectively (See Note 11 in the accompanying unaudited condensed consolidated financial statements).
Income from equity investments
For the nine months ended September 30, 2026, the Company recorded a gain of less than $0.1 million related to its investment in Cohen & Associates LLC, which is recorded at cost and adjusted for the Company’s proportionate share of Cohen & Associates’ net income or loss. Please see Note 18 in the accompanying unaudited condensed consolidated financial statements for further information on the investment in Cohen & Associates.
Liquidity and capital resources
The Company has generated minimal revenues, has incurred operating losses since inception, expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. Until such time as the Company is able to establish a significant revenue stream from the sale of its therapeutic products, it is dependent upon obtaining necessary equity and/or debt financing to continue operations. The Company cannot make any assurances that sales of KETAFREE™, NRX-100, and/or NRX-101 will commence in the near term, revenue from clinics will grow, or that additional financings will be available to it on acceptable terms or at all. This could negatively impact our business and operations and could also lead to the reduction of our operations.
At-The Market Offering Agreement
On April 15, 2024, the Company increased the maximum aggregate offering amount of the shares of common stock issuable under that certain at-the-market offering agreement, dated August 14, 2023 (the “Offering Agreement”), with H.C. Wainwright & Co., and filed a prospectus supplement under the Offering Agreement for an aggregate of $4.9 million (the “ATM Offering”). On August 14, 2024, the Company reduced the amount under the Offering Agreement to $0 and suspended the ATM Offering. On April 17, 2025, the Company reinstated the ATM Offering and filed a prospectus supplement under the Offering Agreement for an aggregate of $20 million.
During the nine months ended September 30, 2026, the Company received aggregate net cash proceeds from the ATM Offering of approximately $11.8 million .
Cash Flow
The following table presents selected financial information and statistics for each of the periods shown below:
| September 30, 2026 |
December 31, 2025 |
|||||||
| Balance Sheet Data: |
||||||||
| Cash |
$ | 19,822 | $ | 7,797 | ||||
| Total assets |
27,815 | 12,956 | ||||||
| Total liabilities |
29,801 | 28,893 | ||||||
| Total stockholders' deficit |
(1,987 | ) | (15,937 | ) | ||||
| Nine Months Ended September 30, |
||||||||
| 2026 |
2025 |
|||||||
| Statement of Cash Flow Data: |
||||||||
| Net cash used in operating activities |
$ | (19,882 | ) | $ | (10,401 | ) | ||
| Net cash used in investing activities |
(896 | ) | (2,561 | ) | ||||
| Net cash provided by financing activities |
32,804 | 18,701 | ||||||
| Net increase in cash |
$ | 12,025 | $ | 5,741 | ||||
Operating Activities
During the nine months ended September 30, 2026, operating activities used approximately $19.9 million of cash, primarily resulting from a net loss of $20.1 million partially offset by net non-cash gain of $2.2 million, and partially increased by changes in operating assets and liabilities that used $2.0 million. The non-cash charges consisted primarily of $1.1 million of common stock issued in exchange for services, $0.5 million of stock-based compensation, $0.3 million of amortization of operating right-of-use assets, $0.2 million of depreciation and amortization, and $0.1 million of other items. The use of cash from changes in operating assets and liabilities consisted primarily of a $1.3 million increase in prepaid expense and other assets, and a $0.7 million net decrease from lower lease liabilities, accounts payable, accrued expenses, and other items, net of a change in accounts receivable.
During the nine months ended September 30, 2025, operating activities used approximately $10.4 million of cash, primarily resulting from a net loss of $29.0 million partially offset by net non-cash losses of $18.5 million, including $8.5 million in change in fair value of warrant liabilities, $8.0 million in change in fair value of convertible promissory notes, $0.2 million of stock-based compensation, $4.2 million loss in convertible note conversion, $1.3 million of loss on Consideration Shares and Warrants, $0.4 million in debt issuance costs, $0.7 million in loss on issuance of Registered Direct Offering, $5.4 million gain on exercise of warrant liabilities and changes in operating assets and liabilities of less than $0.1 million.
Investing Activities
Net cash used in investing activities was $0.9 million for nine months ended September 30, 2026, compared to no cash used in investing activities during the comparable period in 2025. The outflows in the current period were primarily related to capital expenditure for purchase of property and equipment.
Net cash used in investing activities was $2.6 million for the nine months ended September 30, 2025, compared to no cash used in investing activities during the comparable period in 2024. The outflows in the current period were primarily related to the cash consideration paid in connection with the acquisition of Dura, net of cash acquired. The Company did not incur any significant capital expenditure during either period.
Financing Activities
During the nine months ended September 30, 2026, financing activities provided $20.7 million in proceeds from the issuance of a common stock in a confidentially marketed public offering, $11.8 million in proceeds from issuance of common stock in ATM Offering, and $0.5 million in proceeds from the issuance of an insurance loan, partially offset by a repayment of insurance notes of $0.2 million.
During the nine months ended September 30, 2025, financing activities provided $18.7 million of cash resulting from $9.4 million in proceeds from issuance of common stock and warrants related to the RD Offering and $5.0 million in proceeds from the Anson Notes, $4.8 million in proceeds from issuance of common stock in connection with ATM offering, offset by $0.4 million in repayments of and by $0.2 million of proceeds from insurance notes, and $0.2 million in debt issuance costs due to the fair value election on Anson Notes.
Contractual Obligations and Commitments
See Note 9, Debt, and Note 10, Commitments and Contingencies, of the notes to the Company’s consolidated financial statements as of and for the nine months ended September 30, 2026 included elsewhere in this report for further discussion of the Company’s commitments and contingencies.
Milestone Payments
Pursuant to the legal settlement with Sarah Herzog Memorial Hospital Ezrat Nashim (“SHMH”) in September 2018, which included the license of intellectual property rights from SHMH, an ongoing royalty of 1% to 2.5% of NRX-101 gross sales is due to SHMH, together with milestone payments of $0.3 million, upon completion of phase 3 trials and commercial sale of NRX-101. The milestone payments for developmental and commercial milestones range from $0.1 million to $0.8 million. Annual maintenance fees are up to $0.2 million.
Dura Acquisition
Pursuant to the Dura purchase agreement, the Company may be required to pay up to $3.0 million in contingent earn-out payments based on EBITDA performance during the first three years following closing of the acquisition. Payments are subject to the seller’s continued employment and are prorated based on actual results achieved. The purchase price is also subject to customary post-closing adjustments for working capital, cash, and indebtedness.
Off-Balance Sheet Arrangements
The Company is not party to any off-balance sheet transactions. The Company has no guarantees or obligations other than those which arise out of normal business operations.
Critical Accounting Policies and Significant Judgments and Estimates
The Company’s management’s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The preparation of these financial statements requires NRx to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts of expenses during the reporting period. In accordance with GAAP, NRx evaluates its estimates and judgments on an ongoing basis. The most critical estimates relate to stock-based compensation, the valuation of warrants, and the valuation of convertible notes payable. NRx bases its estimates and assumptions on current facts, historical experiences, and various other factors that NRx believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
The Company defines its critical accounting policies as those accounting principles that require it to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on its financial condition and results of operations, as well as the specific manner in which the Company applies those principles. While its significant accounting policies are more fully described in Note 2 to its financial statements, the Company believes the following are the critical accounting policies used in the preparation of its financial statements that require significant estimates and judgments.
Stock-based Compensation
We measure stock option awards granted to employees and directors based on the fair value of the award on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. For restricted stock awards, the grant date fair value is the fair market value per share as of the grant date based on the closing trading price for the Company’s stock. The straight-line method of expense recognition is applied to awards with service-only conditions. We account for forfeitures as they occur.
We estimate the fair value of each stock option award using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock-based awards, the risk-free interest rate for a period that approximates the expected term of our stock-based awards, and our expected dividend yield. Therefore, we estimate our expected volatility based on the implied volatility of publicly traded warrants on our common stock and historical volatility of a set of our publicly traded peer companies. We estimate the expected term of our options using the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future.
The assumptions used in determining the fair value of stock-based awards represent reasonable estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different in the future.
Warrant Liabilities
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, or date of modification, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the Private Placement Warrants, Anson Warrants, Consideration Warrants, and Anson Registered Direct Offering Warrants were estimated using a Black-Scholes valuation approach and the fair value of the Substitute Warrants was estimated using a modified Black Scholes valuation approach which applies a probability factor based on the earnout cash milestone and earnout shares milestone probabilities of achievement at each reporting period.
Convertible Notes Payable
As permitted under ASC Topic 825, Financial Instruments (“ASC 825”), the Company elects to account for its convertible promissory notes, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. As a result of electing the fair value option, direct costs and fees related to the convertible promissory notes are expensed as incurred.
The Company estimates the fair value of the convertible notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration (i.e. expected termination date) of the convertible note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our expected future equity and volume volatility based on the historical volatility of both our common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six months from the issuance date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using Bloomberg's Default Risk function which uses our financial information to calculate a default risk specific to the Company.
The assumptions used in determining the fair value of the convertible note payable represent reasonable estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, the change in fair value of the convertible note payable recorded to other (income) expense could be materially different in the future.
Purchase Price Allocation
We account for business combinations in accordance with ASC Topic 805, Business Combinations, which requires that the assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date and that the excess of consideration transferred over the fair value of net identifiable assets be recorded as goodwill.
The allocation of the purchase price to tangible assets (clinic equipment, leasehold improvements) and identifiable intangible assets (e.g., contracts, clinic trade names) and liabilities assumed (e.g., assumed leases, employee benefit obligations) is based on management’s estimate of fair value as of the acquisition date. This allocation process is considered a critical accounting estimate due to the significant judgments and assumptions inherent in determining the estimated fair values, including the selection of valuation methods (e.g., relief from royalty, multi-period excess earnings, replacement cost), discount rates, expected future cash flows, attrition rates, and useful lives of intangible assets. For the Dura acquisition, the estimated useful lives of acquired intangible assets ranged from 3 to 8 years, and discount rates applied ranged from 12% to 15%. Subsequent adjustments, within the one-year measurement period, may be made as additional information becomes available regarding facts and circumstances that existed at the acquisition date.
Goodwill
Goodwill recorded in connection with Dura acquisitions is attributable to the assembled workforce, anticipated growth in the Florida region, and synergies expected from integrating the clinics into our existing operations. Goodwill is not amortized but is subject to annual impairment testing and more frequently if indicators of impairment exist. We test goodwill for impairment for its reporting units on an annual basis, or when events occur, or when circumstances indicate the fair value of a reporting unit is below its carrying value.
We perform our annual goodwill impairment assessment on December 31st of each year or as impairment indicators dictate.
When evaluating the potential impairment of goodwill, management first assess a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for our products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of our reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the impairment testing methodology using an appropriate valuation method.
We compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.
When required, we may arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.
In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we were required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of September 30, 2026 under the supervision, and with the participation, of our management, including our Chief Executive Officer (who serves as our principal executive officer) and our Chief Financial Officer (who serves as our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2026 in providing reasonable assurance of achieving the desired control objectives.
(b) Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal controls over financial reporting that occurred during the three and nine months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company continues to review its disclosure controls and procedures, including its internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that the Company’s systems evolve with its business.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
See Note 10, Commitments and Contingencies, of the notes to the Company’s unaudited condensed consolidated financial statements as of and for the nine months ended September 30, 2026 included elsewhere in this report for further discussion of certain legal proceedings in which we are involved.
Item 1A. Risk Factors
We have disclosed the risk factors that materially affect our business, financial condition, or results of operations under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 23, 2026 (the “Annual Report on Form 10-K”). Except as set forth below, there have been no material changes from the risk factors previously disclosed. You should carefully consider the risk factors set forth in the Annual Report on Form 10-K and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, or may not be able to assess, also may materially adversely affect our business, financial condition, and/or operating results.
Our contract with DARPA may not be fully funded, may be terminated before completion and subjects us to additional government contracting requirements, any of which could adversely affect our business and financial results.
On September 29, 2026, our subsidiary, NRx Defense Systems, Inc., entered into a prime contract with the Defense Advanced Research Projects Agency, or DARPA, to conduct the SPARC-TMS clinical trial. Although the contract has an aggregate value of approximately $11.2 million, only approximately $6.7 million has been initially obligated by DARPA. Additional funding is subject to, among other things, the availability of government appropriations and DARPA’s exercise of additional funding options, and there can be no assurance that the remaining contract value will ever be funded.
In addition, payments under the contract are contingent upon the achievement and acceptance of specified program milestones. We may incur costs in performing under the contract before receiving payment, and DARPA may determine that a milestone has not been satisfactorily achieved or accepted, which could delay or reduce payments to us. The contract may also be terminated under certain circumstances, including if the program is determined unlikely to achieve its intended objectives. If the contract is terminated, reduced in scope, not fully funded or if payments are delayed or withheld, we may not receive the amount of funding currently anticipated and may be required to fund portions of the SPARC-TMS program from other sources, reduce or delay the program or otherwise modify our development plans.
As a government contractor, we are also subject to contractual and regulatory requirements applicable to U.S. government contracts, which may include audit and recordkeeping requirements, restrictions relating to the use and disclosure of technical data and computer software, intellectual property and data-rights provisions, cybersecurity and security requirements, and other compliance obligations. Our failure to comply with these requirements could result in the withholding or recovery of payments, termination of the contract, damages, penalties, suspension or debarment from future government contracting opportunities or other adverse consequences. In addition, government contracting requirements may increase our costs of compliance and divert management resources. Any of these events could adversely affect our business, financial condition, results of operations and development of NRX-101.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
No unregistered sales of equity securities occurred during the three and nine months ended September 30, 2026 that were not previously reported.
Item 3. Defaults Upon Senior Securities
No defaults upon senior securities occurred during the three and nine months ended September 30, 2026 that were not previously reported.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three and nine months ended September 30, 2026, as such terms are defined under Item 408(a) of Regulation S-K. Additionally, we did not adopt or terminate a Rule 10b5-1 trading arrangement during the three and nine months ended September 30, 2026.
Item 6. Exhibits
| Exhibit Number |
Description |
|
| 10.1 |
Other Transaction for Research Agreement, dated September 29, 2026, between NRx Defense Systems, Inc. and the Defense Advanced Research Projects Agency |
|
| 31.1* |
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 31.2* |
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 32.1** |
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
| 32.2** |
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
| 101† |
Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Unaudited Condensed Consolidated Statements of Operations; (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit); (iv) Unaudited Condensed Consolidated Statements of Cash Flows; and (v) Notes to Unaudited Financial Statements. |
|
| 104 |
Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101) |
| * |
Filed herewith. |
| ** |
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
| † |
In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NRX PHARMACEUTICALS, INC. |
||
| Date: November 16, 2026 |
By: |
/s/ Jonathan Javitt |
| Chairman and Chief Executive Officer |
||
| (Principal Executive Officer) |
||
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NRX PHARMACEUTICALS, INC. |
||
| Date: November 16, 2026 |
By: |
/s/ Michael Abrams |
| Chief Financial Officer |
||
| (Principal Financial Officer) |
||